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Zusammenfassung 
Bedeutung des TL1A/DR3-Signalwegs für die Effektorfunktionen Natürlicher Killerzellen 
Stephanie Claudia Heidemann 
 
Das vor kurzem identifizierte Zytokin der TNF-Superfamilie TL1A (TNFSF15) ist Ligand des 
Todesrezeptors DR3 (TNFRSF25), welcher nach Zellaktivierung in T-Zellen und Natürlichen 
Killerzellen (NK-Zellen) exprimiert wird. TL1A steigert die durch Interleukin (IL)-12 und IL-18 
induzierte Produktion von IFN-γ in T-Zellen um das 10-fache oder mehr. Während ein Großteil der 
NK-Zellen infolge Stimulation mit den Zytokinen IL-12 und IL-18 DR3 exprimiert, führt die 
Kostimulation mit TL1A nur zu einer zweifachen Steigerung der IFN-γ-Produktion. Diese Studie hat 
sich deshalb mit der Fragestellung beschäftigt, ob der TL1A-DR3-Signalweg von Bedeutung ist für 
eine weitere durch IL-12 and IL-18 regulierte Effektorfunktion der NK-Zellen, die Lyse von 
Tumorzellen. Der Einfluß von TL1A auf die Zytotoxizität von mit IL-12 und IL-18 kostimulierten, aus 
mononukleären Zellen des peripheren Blutes (PBMC) isolierten NK-Zellen wurde in 
51Chromfreisetzungstests untersucht. 
Es konnte kein zusätzlicher Einfluß von TL1A auf die durch IL-12 and IL-18 induzierte Zytotoxizität 
der NK-Zellen gegenüber der NK-sensitiven Tumorzelllinie K562 (CML) nachgewiesen werden. 
TL1A war jedoch in der Lage, die Zytotoxizität der NK-Zellen gegenüber der NK-resistenten 
Tumorzelllinie Daudi (Burkitt-Lymphom), welche nur durch Zytokin-aktivierte NK-Zellen lysiert wird, 
zu steigern. TL1A erhöhte die durch IL-12 und IL-18 induzierte Lyse der Daudi-Zellen durch PBMC 
um das zweifache und durch aus PBMC isolierten NK-Zellen um das 7-fache. TL1A steigerte ferner 
die durch IL-12 und IL-18 koaktivierte NK-Zell-vermittelte Lyse der Tumorzellinien WiDr and 
SW837, die von Adenokarzinomen des Kolon und Rektums abgeleitet sind, wenn auch in geringerem 
Ausmaß. Durch die hier nachgewiesene Fähigkeit, die Zytotoxizität von NK-Zellen gegenüber NK-
resistenten Tumoren zu steigern, könnte dem TNF-Superfamilienmitglied TL1A in vivo eine 
Schlüsselrolle als Koaktivator der Zytotoxizität Natürlicher Killerzellen zukommen. 
Mittels Durchflußzytometrie, ELISA bzw. H3-Thymidin-Inkorporationsassays konnte die vorliegende 
Studie ferner belegen, daß aus einer Anzahl von getesteten Zytokinen und Zytokinkombinationen nur 
die Kombination von IL-12 und IL-18 zu einer signifikanten Induktion der DR3-Expression in NK-
Zellen führt, daß TL1A einen synergistischen Effekt auf die Produktion von IFN-γ durch mit optimalen 
und suboptimalen Konzentrationen von IL-12 und IL-18 kostimulierten NK-Zellen hat und daß dieser 
Effekt überwiegend durch die Proliferation von NK-Zellen bedingt ist.  
Tag der mündlichen Prüfung: 27. Februar 2008 
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1 Introduction 
 
1.1 Immunosurveillance 
 
Immunosurveillance is mediated by the innate immunity, characterized by a rapid 
response upon host invasion by pathogens and transformed cells which does not 
require priming with specific antigens (76), and the adaptive immunity which 
provides antigen-specific recognition of pathogens and cancerous cells, an accelerated 
response upon re-exposure with the antigen, and long-term memory (84).  
The innate immune system comprises the epithelial barriers, phagocytic cells (e.g. 
neutrophils and macrophages), the complement system, natural killer (NK) cells and 
cytokines which regulate the functions of the innate cells (76). Adaptive immunity is 
mediated by B and T cells (84). 
 
1.2 Cellular effectors of immunosurveillance 
 
1.2.1 Natural killer cells 
 
Natural killer cells are white blood lymphocytes of the innate immune system, 
phenotypically characterized as CD56+ and CD3-, which play an important role in 
innate immune defense by eliminiating invading infectious pathogens and tumor cells 
through cytokine production and MHC-nonrestricted cytotoxicity.  
NK cells, which comprise approximately 15% of all circulating lymphocytes, are also 
found in peripheral tissues, e.g. the liver, peritoneal cavity and placenta. While resting 
NK cells circulate in the blood, cytokine-activated NK cells are capable of 
extravasation and infiltration into most tissues invaded by pathogens and tumor cells 
(76).  
NK cells can be divided into subsets based on their surface phenotype. It was 
hypothesized that phenotypically distinct NK cell population represent independent 
subsets with specialized NK cell effector functions. Recent studies however support 
the conclusion that the distinct phenotype of the subsets rather correlates with 
developmental stages or states of cell activation (68). 
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The pattern of cytokine production depends on the stage of NK cell differentiation. 
While immature NK cells produce T helper 2 cytokines (e.g. IL-4, IL-5 and IL-13, 
which regulate antibody-mediated responses), mature NK cells lose this ability, but 
acquire the ability to produce T helper 1 cytokines (i.e. pro-inflammatory cytokines, 
like IFN-γ, which are essential for the defense against intracellular pathogens) 
(68;76).  
NK cells produce the immunomodulatory cytokines IFN-γ, TNF-α, GM-CSF which 
determine the early innate immune response and also regulate the delayed T cell 
response. When stimulated by products of infectious pathogens, antigen-presenting 
cells, e.g. macrophages and dendritic cells, induce NK cell production of IFN-γ via 
secretion of cytokines, e.g. interleukin (IL)-12, IL-15 and IL-18, for which NK cells 
constitutively express receptor complexes (12;22;72;87).  
NK-cell secretion of IFN-γ plays an essential role in the immune defense against 
pathogens, and recent evidence further revealed the multiple antitumor effects of NK 
cell IFN-γ production. The proposed functions of IFN-γ include induction of antigen 
expression by up-regulation of MHC class I and II on many cell types, coordination of 
the interaction of leucocytes with the endothelium, regulation of cell proliferation and 
sensitivity to apoptosis, stimulation of the bactericidal activity of phagocytes and 
inhibition of angiogenesis (76). 
 
NK cells discriminate between normal cells expressing an adequate amount of major 
histocompatibility complex (MHC) class I and cells with loss of or altered MHC class 
I expression as a consequence of tumor transformation or viral infection. Engagement 
of MHC class I-specific inhibitory receptors by classical or non-classical MHC class I 
molecules downregulates NK cell effector functions. Activating NK receptors include 
MHC class I-specific receptors, Non-MHC class I-specific receptors, e.g. natural 
cytotoxicity receptors (NKp30, NKp46, NKp44) and NKG2D which recognizes 
pathogen-associated and stress- and tumor-induced MHC class I-related ligands, and 
coreceptors (2B4 (CD24), CD16 (FcgammaRIII) etc.). Engagement of activating 
receptors by their ligands induces NK cell cytotoxicty, blastogenesis, cytokine 
production, and/ or migration. The FcgammaRIII (CD16) receptor on NK cells 
recognizes antigen-bound IgG antibodies and mediates antibody-dependent-cellular-
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cytotoxicity (ADCC). A variety of co-stimulatory and adhesion molecules can also 
trigger cytotoxicity. NK cell effector function is the result of an integration of signals 
from inhibitory receptors and activating NK receptors and dependent upon the density 
and selection of MHC class I and MHC class I-related molecules expressed on target 
cells (17;22;41;54). 
 
Cytolytic activity of NK cells is generally mediated through the Ca2+-dependent 
granule exocytosis pathway involving perforin/granzyme release. The pore-forming 
protein perforin induces loss of osmotic stability and target cell necrosis (34) and 
permits the influx of granzymes which induce target cell apoptosis by activation of 
caspases and cleaving of Bcl2 familiy members (31;70). Perforin-dependent target 
cell membrane damage and necrosis are measured by the 51Cr-release assay (92). It 
was recently demonstrated that tumor elimination mediated by NKG2D receptor-
ligand interaction is perforin-dependent (30).  
An alternative, Ca2+-independent mechanism of NK cytotoxicity involves Fas/CD95 
ligand-mediated apoptosis upon interaction of Fas/CD95 receptor-positive target cells 
with Fas ligand, expressed or induced on NK cells (89;93). A role of TRAIL and 
other TNF family ligands in apoptotic killing of tumor targets by NK cells has also 
been described (37;85).  
Recent evidence suggests that the cytokines to which NK cells respond and the 
expression patterns of NKG2D ligands on tumor cells determine if NK cells exert 
their lytic function through perforin-, Fas ligand-, or TRAIL-dependent pathways 
(77). 
 
1.2.2 T cells 
 
T cells, which mediate adaptive immunity, are capable of generating an infinitely 
diverse repertoire of antigen-specific receptors. They can proliferate clonally very 
rapidly, and confer long-term protection after the initial immunization with an antigen 
with an accelerated response upon re-exposure (84). 
T cells play an important role in tumor immunosurveillance (47;84). They can be 
divided in two sub-lineages based on the type of antigen-receptor expressed, i.e. αβ T 
cells and γδ T cells. Both subsets express surface CD3 and a rearranged T-cell 
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receptor (TCR) (84). αβ T cells express the α and β chains of the TCR, while γδ T 
cells express the γ and δ chain rearrangement (47). αβ T cells comprise the majority of 
T cells in the circulation and lymphoid tissues, and they include a subset called 
natural killer T (NKT) cells, which expresses several NK cell surface receptors (84). 
Most γδ T cells and a subset of NKT cells are unconventional T cells which, like NK 
cells, are not restricted to classical MHC class-I or MHC class II-bearing specific 
peptides (80).  
The functional properties of γδ T cells are in general more characteristic of the innate 
immune system despite the expression of a rearranged TCR. A large number of γδ T 
cells are found in the human intestinal epithelium and the murine skin. γδ T cells 
mount a rapid immune response against transformed cells, while conventional T cells 
have a long activation period to permit clonal expansion (84). Like NK cells, some γδ 
T cells recognize the MHC class I-related proteins A and B (MICA/B) via the 
receptor NKG2D, but also via the T cell receptor (84). Unlike αβ T cells, in vitro 
activated γδ T cells were reported to mediate cytotoxicity against several tumor cell 
lines, including Daudi cells (47). 
Although innate immune cells form an important first line of defense against 
cancerous cells, complete tumor rejection depends on the adaptive immune system, 
i.e. the majority of conventional T cells (84).  
 
1.3 IL-12 and IL-18 
 
IL-12 is primarily produced by antigen-presenting cells and plays an important role in 
Th1-biased, cell-mediated immune responses induced by intracellular pathogens, but 
it is also involved in the pathogenesis of chronic inflammatory disease (25;83;88). IL-
12 powerfully stimulates NK and T cells. The effects of IL-12 on these cells include 
induction of IFN-γ production in the presence of accessory cells (14;40); enhancement 
of cytolytic activity (15); and stimulation of proliferation of activated cells (24).  
IL-18 is an IL-1-related cytokine, produced by cells of the monocyte lineage, that was 
first described as an IFN-γ-inducing factor (IGIF) based on its ability to induce high 
level IFN-γ secretion by both NK cells and T cells (56;59). IL-18 also mediates other 
immunoregulatory functions shared with IL-12 including enhancement of NK lytic 
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activity and proliferation of activated T cells (59;91). IL-18-deficient mice show 
reduced production of IFN-γ, impaired NK cell activity, and a defective Th1 cell 
response, as do IL-12-deficient mice. In mice lacking both cytokines NK lytic activity 
and Th1 differentiation are further impaired which demonstrates the synergistic 
function of IL-12 and IL-18 in vivo (86).  
NK cells, unlike T cells, constitutively express high affinity receptors for both IL-12 
and IL-18. The synergistic effects of IL-12 and IL-18 could be the consequence of 
reciprocal up-regulation of receptors and of cooperative action at the transcriptional 
level resulting in optimal activation of IFN-γ transcription and other effector functions 
of T and NK cells (3;12;13;35;55;82). 
 
IL-18, which enhances the expression of Fas ligand on NK cells (90), exerts its 
significant antitumor activity primarily via a Fas-dependent pathway (29). IL-12, 
however, augments cytotoxicity of NK-like cells by inducing expression of perforin 
(20), and IL-12-induced antitumor effects are predominantly mediated by the perforin 
pathway (29). 
Recent evidence implies that NK cell recognition of tumor cells is a requirement for 
effective immunotherapy of cancer by cytokines (77). In murine models of NK cell-
mediated tumor suppression, the perforin-dependent antitumor activity of IL-2 or IL-
12 was initiated via the NKG2D receptor-ligand recognition pathway, and cytokines 
that stimulated perforin-mediated cytotoxicity were more effective against tumor 
metastases expressing NKG2D ligands. By contrast, the Fas-dependent IL-18-induced 
tumor rejection by NK cells did not involve the NKG2D receptor-ligand pathway but 
required tumor susceptibility to Fas ligand. Cotreatment with IL-2 and IL-18 
stimulated both perforin- and Fas ligand-dependent NK cell lytic functions with 
potent synergistic tumor-suppressive effects (77). A similar action is conceivable for 
the combination of IL-12 and IL-18.  
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1.4 The TL1A/DR3 pathway 
 
TL1A (TNFSF15), a new TNF-like molecule, was recently described as ligand of the 
TNF receptor (TNFR)-superfamily members DR3 (TNFRSF25) and TR6/DcR3 (52).  
The TNF superfamily of proteins (TNF SFP) consists of 18 type 2 proteins that can 
have membrane-bound or soluble forms. Their receptors, which compose the TNFR 
superfamily of proteins, are type 1 transmembrane proteins characterized by cysteine-
rich domains (46). 
Ligand-receptor interaction of the TNF/TNFR superfamilies of proteins (TNF/TNFR 
SFP) activates signaling pathways involved in many biological processes, e.g. tissue 
homeostasis, cell death, development, organogenesis, and innate and adaptive 
immunity. Members of the TNF/TNFR SFP are expressed on cells of the immune 
system and play a key regulatory role in multiple functions of the immune response, 
including defense against microorganisms, inflammation, and autoimmunity (46).  
The TNFR superfamily can be divided in two groups based on two principal classes 
of cytoplasmic adaptor proteins and distinct modes of signaling (46). The first group 
is characterized by a TRAF (TNFR-associated factor) binding domain. Ligation of the 
TRAF binding domain by TNFR-associated factors activates signal transduction 
pathways resulting in NF-κB activation and initiation of transcription. The second 
group contains a death domain (DD). Death domain-containing receptors were 
initially shown to induce apoptosis via the activation of caspases. Recent evidence has 
shown an involvement of DD-containing receptors in nonapoptotic 
immunomodulatory functions, e.g. T cell activation by Fas (52). DR3 belongs to this 
group of receptors. The members of the third group, which include DcR3/TR6, are 
called decoy receptors. They lack a cytoplasmic domain and were thought to inhibit 
signal transduction by competing with the signal-transducing receptor for the ligand.  
 
DcR3 binds to FasL and LIGHT and inhibits FasL-induced apoptosis. Recent studies 
revealed its downregulating function in immune responses (52;96). Many human 
tumors overexpress DcR3, and DcR3 is believed to be released by tumor cells as 
soluble decoy receptor to escape the host immune response by neutralizing the 
cytotoxic effects of FasL, LIGHT and TL1A (96). 
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DR3 is a death-domain-containing receptor with highest homology to TNFR1 (52). 
Expression of DR3 is confined to lymphocytes and can be induced by activation (75). 
To date, TL1A is the only known ligand of DR3 (97). TL1A is a longer variant of  
VEGI, an endothelium-derived factor shown to inhibit endothelial cell growth and 
tumor progression (52). While resting T cells, B cells, NK cells, DC, and monocytes 
did not express TL1A mRNA, IL-1a, TNF or PMA induced transcript in human 
umbilical vein endothelial cells (HUVEC) (52). Like most TNF ligands, TL1A has a 
membrane-bound form, and ectopic expression of the complete cDNA results in the 
release of a bioactive, truncated form (52;71). 
In anti-CD3, anti-CD28 stimulated T cells, TL1A enhances IL-2 responsiveness and 
secretion of the proinflammatory cytokines IFN-γ and GM-CSF (52). TL1A further 
has a synergistic effect on IL-12 and IL-18-induced IFN-γ production in human T 
cells and NK cells (64). There is evidence that TL1A is involved in the pathogenesis 
of inflammatory bowel disease (71), atherosclerosis and rheumatoid arthritis (97). 
TL1A has been reported to inhibit angiogenesis and to induce metalloproteinase and 
IL-8 gene expression (97). 
In TF-1 cells, which express DR3 endogenously, TL1A binding activates NF-κB and 
MAPK (ERK, JNK, and p38) pathways by inducing the formation of a DR3 signaling 
complex involving TNFR1-associated death domain protein (TRADD), TNFR-
associated factor-2 (TRAF2), and receptor interactive protein (RIP), but it does not 
induce apoptosis (95). The results suggested that DR3-induced activation of NF-κB 
was responsible for resistance to apoptosis in TF-1 cells. Moreover, interaction of 
TL1A with its receptor DR3 was recently shown to induce IL-8 gene expression by 
activating TRAF2 and NF-κB via the TAK1/ASK1-MKK4/MKK7-JNK2 kinase 
cascade (97). 
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1. 5 Aims of the study 
 
Papadakis et al. recently reported that TL1A synergizes with IL-12/IL-18 to augment 
IFN-γ production in resting human peripheral blood T and NK cells. DR3 is not 
expressed on unstimulated T and NK cells, but it is induced on a small subset of T 
cells and on up to 70% of NK cells by IL-12 and IL-18. However, while engagement 
of DR3 by TL1A augments IL-12/IL-18 induced IFN-γ production 3-15 fold in T cell 
cultures, the increase in NK cell cultures is a modest two-fold. In T cells, TL1A 
enhances IFN-γ production by increasing both the number of IFN-γ producing cells 
and the amount of IFN-γ produced per cell, whereas in NK cells, only the number of 
IFN-γ producing cells is augmented in response to TL1A (64). The synergistic effect 
of TL1A on NK cell IFN-γ production therefore seems to be solely due to stimulation 
of NK cell proliferation and not to an enhanced IFN-γ production per cell. Given the 
induction of DR3 on most NK cells by IL-12/IL-18, this study investigated if TL1A 
also regulates another function of cytokine activated NK cells, cytotoxicity against 
tumor cells.  
This study also analyzed if other cytokines known to activate NK cells induce DR3 
expression, and it aimed at identifying concentrations of the combined DR3-inductive 
cytokines IL-12 and IL-18 which result in maximal effectiveness of the TL1A-DR3 
pathway. A dose-kinetic analysis of the effect of IL-12/IL-18 on NK cell IFN-γ 
production, with and without co-stimulatory TL1A, was therefore performed. This 
study further investigated whether the synergistic effect of TL1A on IL-12/IL-18-
induced IFN-γ production is mainly due to stimulation of NK cell proliferation, as 
suggested by previous data (64). To this end, NK cell DNA replication was measured 
in a H3-Thymidine incorporation assay. 
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2 Materials 
 
2.1 Peripheral blood cells 
 
Blood for the isolation of peripheral blood mononuclear cells (PBMC) and natural 
killer (NK) cells was obtained from normal donors after informed consent in 
accordance with the Human Subjects policy of the Cedars-Sinai Medical Center 
Institutional Review Board. 
 
2.2 Tumor cell lines 
 
K562        ATCC CCL-243 
The cell line K562 was derived from the pleural effusion of a patient with chronic 
myelogenous leukemia in terminal blast crisis (48;49). K562 are multipotential, 
hematopoietic malignant cells which are capable of spontaneously differentiating into 
progenitors of the erythrocytic, granulocytic and monocytic series (48). The strain 
purchased from ATCC most closely resembles the B population. The Philadelphia 
chromosome was not detected in 15 metaphases examined by ATCC. The line is 
Ebstein-Barr virus nuclear antigen-negative (1). K562 cells, which are highly 
sensitive to lysis by NK cells, are standard target cells for measurements of 
cytotoxicity in 51Cr-release assays (23). 
 
Daudi        ATCC CCL-213 
The Daudi cell line was derived from a Burkitt’s lymphoma (39). Daudi is a well 
characterized B lymphoblast cell line which is frequently used in studies of 
mechanisms of leukemogenesis. The cells are negative for beta-2-microglobulin. The 
line carries the Epstein-Barr virus and is positive for Ebstein-Barr virus nuclear 
antigen, viral capsid antigen and surface immunoglobulin (1). While the line is 
resistant to lysis by unstimulated NK cells, it can be used for measurements of 
cytotoxicity of activated NK cells (23). 
 
SW837        ATCC CCL-235 
SW837 cells were established from a rectal adenocarcinoma and are highly resistant 
to lysis by unactivated NK cells (our data). The epithelial cells display a mutation in 
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the p53 gene (Cytosine Æ Thymine mutation in codon 248 (73)). The cells are 
negative for expression of colon specific antigen (CSAp) and colon antigen 3 and 
express the following antigens: HLA A23, A32, B15, B35; blood type O; Rh+ (1). 
SW837 are capable of synthesizing carcinoembryonic antigen (CEA) (44) and keratin 
(1). 
 
WiDr        ATCC CCL-218 
The NK-resistant cell line (our data) was derived from a patient with a colorectal 
adenocarcinoma. The cells display a mutation of the p53 antigen (Guanine Æ 
Adenine mutation). WiDr express HLA A24, A32, B15, B18 and synthesize 
carcinoembryonic antigen (CEA), colon specific antigen (CSAp), transforming 
growth factor beta and keratin. The cells are negative for colon antigen 3 expression 
(1). 
 
2.3 Cytokines  
 
Ionomycin     Sigma-Aldrich Inc. (St.Louis, MO) 
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich Inc. (St.Louis, MO) 
Recombinant IFN-α    R&D Systems (Minneapolis, MN) 
Recombinant IFN-β    R&D Systems (Minneapolis, MN) 
Recombinant IFN-γ     R&D Systems (Minneapolis, MN) 
Recombinant IL-2      R&D Systems (Minneapolis, MN)  
Recombinant IL-12     Peprotech (Rocky Hills, NJ) 
Recombinant IL-15     Peprotech (Rocky Hills, NJ) 
Recombinant IL-18    R&D Systems (Minneapolis, MN) 
Recombinant TL1A (aa72-251)  Human Genome Sciences, Inc. 
(Rockville, MD) 
Recombinant TNF-α    Peprotech (Rocky Hills, NJ) 
 
2.4 Antibodies 
 
2.4.1 Flow cytometry 
Anti-CD3 mAb, FITC-conjugated   Caltag (South San Francisco, CA) 
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(mouse IgG2a) 
Anti-CD3 mAb, PE-conjugated   Caltag (South San Francisco, CA) 
(mouse IgG2a) 
Anti-CD14 mAb, FITC-conjugated   Caltag (South San Francisco, CA) 
(mouse IgG2a) 
Anti-CD19 mAb, FITC-conjugated  Caltag (South San Francisco, CA) 
(mouse IgG1) 
Anti-CD56 mAb, TC-conjugated   Beckman Coulter (Fullerton, CA) 
(mouse IgG1) 
Anti-DR3 specific mAb    Human Genome Sciences, Inc., 
(mouse IgG1; clone F05) (Rockville, MD) 
Anti-IFN-γ mAb, PE-conjugated  BD PharMingen (San Diego, CA) 
Anti-mouse IgG1 mAb, PE-conjugated  Caltag (South San Francisco, CA) 
Blocking antibodies mouse IgG1, IgG2a,  Jackson ImmunoResearch (West Grove, 
IgG2b  PA) 
Isotype mouse IgG1, TC-conjugated   Caltag (South San Francisco, CA)  
Isotype mouse IgG1, unconjugated  Caltag (South San Francisco, CA)  
Isotype mouse IgG1, PE-conjugated  BD PharMingen (San Diego, CA) 
Isotype mouse IgG2a, FITC conjugated  Caltag (South San Francisco, CA) 
Isotype mouse IgG2a, PE conjugated  Caltag (South San Francisco, CA) 
 
2.4.2 ELISA 
Anti-human IFN-γ mouse Ab   BD Pharmingen (San Diego, CA) 
Secondary anti-human IFN-γ biotinylated  BD Pharmingen (San Diego, CA) 
mAb      
Streptavidin-Alkaline phosphatase Jackson Immuno Research (West Grove, 
PA) 
 
2.5 Chemicals and buffers 
 
2.5.1 Isolation of PMBC and NK cells 
Heparin      Sigma Chemical Co. (St. Louis, MO) 
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HBSS-10x, w/o Ca2+ and Mg2+   Mediatech Inc. (Herndon, VA) 
Lymphocyte Separation Medium   Fisher Scientific (Tustin, CA) 
Sodium Bicarbonate (7.5% sol.)  Mediatech Inc. (Herndon, VA) 
 
2.5.2 Cell culture 
Fetal bovine serum     Omega Scientific (Tarzana, CA) 
Gentamicin Sulfate Solution   Omega Scientific (Tarzana, CA)  
Minimum Essential Medium Eagle with  Mediatech Inc. (Herndon, VA) 
Earle's salts and l-glutamine  
RPMI 1640 with 2 mM glutamine and Mediatech Inc. (Herndon, VA) 
25 mM HEPES buffer  
Trypsin EDTA (0.25% Trypsin and   Gibco Invitrogen Corp. (Grand Island, 
1mM EDTA-4Na)  NY) 
 
2.5.3 Flow cytometry 
Bovine serum albumin   Sigma Chemical Co. (St. Louis, MO) 
Brefeldin A     EMD (c/o Calbiochem; La Jolla, CA) 
Paraformaldehyd      Sigma Chemical Co. (St. Louis, MO) 
10x PBS, w/o Ca 2+ and Mg 2+   Mediatech Inc. (Herndon, VA) 
Saponin      Sigma Chemical Co. (St. Louis, MO) 
Sodium Azide      Sigma Chemical Co. (St. Louis, MO) 
 
2.5.4 ELISA 
2-propanol     J.T. Baker (Phillipsburg, NJ) 
β-Nicotinamide adenine dinucleotide  Sigma Chemical Co. (St. Louis, MO) 
phosphate (NADP+) 
Alcohol Dehydrogenase (ADH)  Sigma Chemical Co. (St. Louis, MO) 
Diaphorase      Sigma Chemical Co. (St. Louis, MO) 
Dimethyl Sulfoxide (DMSO)   Sigma Chemical Co. (St. Louis, MO) 
H3BO4     Sigma Chemical Co. (St. Louis, MO) 
Iodonitrotetrazolium chloride (INT)  Sigma Chemical Co. (St. Louis, MO) 
KH2PO4     Fisher Scientific (Tustin, CA) 
MgCl2 2H2O     Fisher Scientific (Tustin, CA) 
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NaCl     Fisher Scientific (Tustin, CA) 
NaH2PO4 2H2O     Fisher Scientific (Tustin, CA) 
Na2HPO4     J.T. Baker (Phillipsburg, NJ) 
NaN2     Sigma Chemical Co. (St. Louis, MO) 
NaOH     J.T. Baker (Phillipsburg, NJ) 
PBS 10x, w/o Ca2+ & Mg2+   Mediatech Inc. (Herndon, VA) 
TRIS Base      Fisher Scientific (Tustin, CA) 
Tris-HCl     J.T. Baker (Phillipsburg, NJ) 
Tween 20     Fisher Scientific (Tustin, CA) 
 
2.5.5 51Cr-release assay 
Chromium-51 Radionuclide, 1mCi  Perkin Elmer Life Sciences  
(37MBq), Specific Activity: 400-1200Ci  (Downers Grove, IL)  
(14.8-44.4TBq)/g, Sodium Chromate in  
Normal Saline (pH 8-10) 
LKG Hi-Load (High safety scintillation Perkin Elmer (Downers Grove, IL;  
Cocktail)  formerly Wallac) 
Triton X-100     Fisher Scientific (Tustin, CA) 
 
2.5.6 H3-Thymidine incorporation assay 
BetaplateScint  Perkin Elmer (Downers Grove, IL;  
formerly Wallac) 
 
2.6 Composition of prepared solutions 
 
2.6.1 PBMC isolation 
1x HBSS  10x HBSS, w/o Ca2+ and Mg2+, sterile 
destilled water, pH 7.0 (pH equilibration 
with Sodium Bicarbonate (7.5% sol.)) 
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2.6.2 NK cell Isolation 
Buffer (PBS/0.5% BSA) 10x PBS w/o Ca2+ and Mg2+, sterile 
destilled water, 0.5% (w/v) BSA, pH 7.2, 
degassed 
 
2.6.3 Cell culture 
Minimum Essential Medium Eagle   Minimum Essential Medium Eagle 
with Earle's salts and l-glutamine supplemented with 10% (v/v) fetal 
bovine serum and 50 μg/ml gentamycin 
RPMI culture medium  RPMI 1640 with 2 mM glutamine and 25 
mM HEPES buffer, supplemented with 
10% (v/v) fetal bovine serum (heat 
inactivated) and 50 μg/ml gentamicin  
 
2.6.4 Flow cytometry 
Fixing solution  2% (w/v) Paraformaldehyd in 1x PBS 
(PBS/2% (w/v) Paraformaldehyd) w/o Ca2+ and Mg2+, sterile-filtered 
1x PBS  10x PBS w/o Ca2+ and Mg2+, sterile 
destilled water, pH 7.2 
Permeabilizing solution 0.5% (w/v) BSA, 0.02% (w/v) Sodium 
Azide, 0.1% (w/v) Saponin in 1x PBS 
w/o Ca2+ and Mg2+, sterile-filtered 
Staining solution (PBS/0.5% (w/v) BSA) 0.5% (w/v) BSA, 0.02% (w/v) Sodium 
Azide in 1x PBS w/o Ca2+ and Mg2+, 
sterile-filtered 
 
2.6.5 ELISA 
Amplifier  1.0 mg Diaphorase, 10.0 mg INT 
(dissolve in 0.3 ml DMSO), 1.5 mg 
ADH, 0.6 ml 2-propanol in 10.0 ml 
Amplifier Buffer (0.025 M PO4, pH 8.8) 
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Amplifier Buffer (10x) 17.8 g Na2HPO4 (0.25 M PO4) in 500 ml 
destilled water, equilibrate pH by adding 
KH2PO4 (3.4 g KH2PO4 in 100 ml 
destilled water) to 500 ml of Na2HPO4 
until pH reaches 8.8 
Borate Buffered Saline (10x) 51.5 g H3BO4, 36.5 g NaCl in 500 ml 
destilled water, pH 8.5 (using NaOH) 
PBS/Tween (10x)  2.89 g NaH2PO4 2H2O, 11.94 g 
Na2HPO4, 87.67 g NaCl, 2.0 g NaN2, 5.0 
ml Tween 20 in 1000 ml destilled water  
Tris/NaCl (10x)  60.5 g Tris Base, 87.67 g NaCl, 2.00 g 
NaN2, 5.0 ml Tween 20, pH to 7.5 with 
10 N HCl (approximately 37 ml) 
Substrate  1.6 mg NADP+ in 5.0 ml of Substrate 
Buffer (0.075 M Tris Base, pH 8.8) 
Substrate Buffer (10x) 45.43 g Tris Base (0.75 M Tris Base), 
1.52 g MgCl2 2H2O in 500 ml destilled 
water, pH to 8.8 with 10 N HCl 
 
2.7 Kits 
 
2.7.1 NK cell Isolation 
NK Cell Isolation Kit II   Miltenyi Biotec Inc. (Auburn, CA) 
- NK Cell Biotin-Antibody Cocktail: 
Cocktail of biotin-conjugated monoclonal  
antibodies against CD3, CD4, CD14,  
CD15, CD19, CD36, CD123 and  
Glycophorin A 
- Anti-Biotin Micro-Beads: 
Microbeads conjugated to a monoclonal 
antibiotin antinody (clone: Bio3-18E7:2;  
mouse IgG1) 
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2.7.2 Flow cytometry 
Fix and Perm Cell Permeabilization Caltag (South San Francisco,  
Reagents   CA) 
- Fixation Medium (Reagent A) 
- Permeabilization Medium (Reagent B) 
 
2.8 Laboratory equipment 
 
Centrifuges 
- IEC Centra MP4R Thermo Electron Cooperation (Waltham, 
MA; formerly International Equipment 
Company) 
- IEC Centra HN  Thermo Electron Cooperation (Waltham, 
MA; formerly International Equipment 
Company) 
- Sorvall TC 6   Thermo Electron Cooperation (Waltham, 
MA) 
Emax plate reaeder Molecular Devices (Menlo Park, CA) 
Flow-cytometer      Becton Dickinson (Mountain View, CA) 
Harvester 96®      Tomtec (Hamden, CT) 
Heat Sealer  Packaging Aids Corporation (San Rafael, 
CA) 
Incubator  Thermo Electron Cooperation (Waltham, 
MA; formerly Forma Scientific) 
Microscopes 
- Olympus Microscope CH2   Olympus (San Diego, CA) 
- Olympus Microscope CK2   Olympus (San Diego, CA) 
Steril Card Hood, class II type A/B3  The Baker Company (Sanford, ME) 
VarioMACSTM Separator   Miltenyi Biotec, Inc. (Auburn, CA) 
Vortex Mixer     Barnstaed Thermolyne (Dubuque, IA) 
Wallac 1450 Microbeta Liquid Scintillation  Perkin Elmer (Downers Counter Grove, 
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Counter  IL; formerly Wallac) 
2.9 Other materials 
 
2.9.1 Cell culture 
12-well Culture Cluster, Flat bottom  Corning Inc. Life Sciences (Acton, MA) 
with lid 
24-well Culture Cluster, Flat bottom Corning Inc. Life Sciences (Acton, MA) 
with lid 
96-well Culture Cluster, Flat bottom  Corning Inc. Life Sciences (Acton, MA) 
with lid 
Cell Culture Flasks, 225 cm2   Corning Inc. Life Sciences (Acton, MA) 
MACSTM Cell Separation Column LS Miltenyi Biotec Inc. (Auburn, CA) 
Pipet tips, filtered     VWR Scientific Products (Cerritos, CA) 
Tissue Cultue Flasks, 250 ml Greiner Bio-One North America Inc. 
(Monroe, NC) 
Tissue Cultue Flasks, 50 ml Greiner Bio-One North America Inc. 
(Monroe, NC) 
 
2.9.2 ELISA 
96-well plates, Flat bottom Greiner Bio-One North America Inc. 
(Monroe, NC) 
 
2.9.3 51Cr-release assay 
96-well plates, V-bottom Greiner Bio-One North America Inc. 
(Monroe, NC) 
AeraSeal Sealing Film Soft Rubber Roller Research Products International (Mount 
Prospects, IL) 
Sealing Film, polypropylene Research Products International (Mount 
Prospects, IL) 
TempPlate RT Optically Clear Sealing Film USA Scientific (Ocala, FL) 
 
2.9.4 H3-Thymidine incorporation assay 
Bags for Wallac 1450 Microbeta Liquid  Perkin Elmer (Downers Grove, IL) 
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Scintillation Counter 
Filtermat A     Perkin Elmer (Downers Grove, IL) 
 
2.10 Software 
 
Elisa Master®  developed by R. Deem (Inflammatory 
Bowel Disease Center, Cedars-Sinai 
Medical Center, Los Angeles, CA) 
CellQuest     Becton Dickinson (Mountain View, CA) 
JMP IN 5.1 data analysis software  SAS Institute (Cary, NC) 
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3 Methods 
 
3.1 Isolation and culture of PBMC, NK cells, and non-NK cells 
 
3.1.1 Isolation of PBMC 
Test principle 
The density-gradient centrifugation technique with Ficoll-Hypaque is used to isolate 
peripheral blood mononuclear cells from whole blood by taking advantage of the 
different specific densities of blood cells. Hereby, anticoagulated blood is layered 
over Ficoll-Hypaque and centrifuged. Red blood cells and polymorphonuclear 
leucocytes have a higher specific density than Ficoll-Hypaque and therefore settle 
below the Ficoll-Hypaque layer. Mononuclear cells and platelets are less dense than 
Ficoll-Hypaque, therefore band over it, and can be collected from the plasma/Ficoll-
Hypaque interface. 
 
Procedure 
60, 120 or 180 ml of peripheral blood were obtained from normal donors by 
venipuncture and treated with 1000 units of Heparin per ml of blood. PBMC were 
isolated on standard Ficoll-Hypaque density gradients. To this end, 15 ml of 
Lymphocyte Separation Medium were carefully overlayered with 30 ml of blood in 
50 ml conical centrifuge tubes and centrifuged at 1000 x g for 20 minutes without 
brake at room temperature. The interface layer of each density gradient, consisting of 
mononuclear cells, was removed with a 10 ml glass pipet and placed into a 50 ml 
conical centrifuge tube for two subsequent cycles of washing of the cells. To this end, 
the cells were diluted with 40 ml of 1 x HBSS and centrifuged at 400 x g for 5 min. 
Next, the supernatant was decanted, the pellet resuspended and the cells of two 50 ml 
tubes were united in one 15 ml tube. Each 15 ml tube was filled with 14 ml of 1 x 
HBSS and centrifuged at 400 x g. The cell pellet was resuspended in RPMI 1640 
containing 2 mM glutamine and 25 mM HEPES buffer, supplemented with 10% (v/v) 
fetal bovine serum and 50 μg/ml gentamicin.  
PBMC were depleted of monocytes by adherence for two hours or overnight. 
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3.1.2 Isolation of NK cells and non-NK cells 
Test principle 
The magnetic-activated cell sorting (MACS) technology permits the enrichment or 
depletion of a particular cell type using magnetic cell labeling (53). For indirect 
magnetic cell labeling, cells are labeled with an unconjugated, biotinylated, or 
flourochrome-conjuagted primary monoclonal antibody directed against a 
characteristic surface marker of the cell type of interest (e.g. CD3 for T-cells, CD56 
for NK cells). A cocktail of antibodies can also be employed to isolate or deplete a 
number of cells simultaneously. In a second step, cells are magnetically labeled with 
superparamagnetic MACS MicroBeads which are coupled to an appropriate 
secondary reagent (e.g. anti-immunoglobulin, anti-biotin, streptavidin, or anti-biotin, 
respectively). The cells are then passed over a magnetic separation column (MACS 
column), which is placed in the strong magnetic field of the MACS Separator. The 
magnetically labeled cells are retained in the column, while non-labeled cells pass 
through. After removal of the column from the magnetic field, the magnetically 
retained cells can be eluted from the column. The manufacturer states that the 
biodegradable, submicroscopic MicroBeads do not affect function, viability or light 
scattering properties of the magnetically labeled cells. Two magnetic cell separation 
strategies can be employed: positive and negative selection. Positive selection 
involves magnetic labeling of the cells of interest which are isolated by retention in a 
MACS column, followed by elution from the column after removal from the magnetic 
field. Negative selection depends on depletion of the non-target cells by magnetic 
labeling and subsequent retention in the MACS column, while the enriched unlabeled 
target cells pass through the column. 
 
Procedure 
In this study, NK cells were isolated from PBMC by negative selection (NK Cell 
Isolation Kit II, Miltenyi Biotec, Auburn, CA) and thus not exposed to potentially 
stimulatory mAb. Hereby, non-NK-cells were indirectly magnetically labeled with a 
cocktail of biotin-conjugated mononclonal antibodies, as primary labeling reagent, 
and anti-biotin monoclonal antibodies conjugated to MicroBeads, as secondary 
labeling reagent. The magnetically labeled non-NK cells were depleted by retention in 
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a MACS column in the magnetic field of a MACS Separator, while the unlabeled NK 
cells passed through the column.  
 
Magnetic labeling  
The NK cell isolation was performed according to the manufacturer’s protocol, using 
from 10x107 to 15x107 PBMC obtained by density gradient centrifugation as 
described above. The suspension of PBMC was centrifuged at 400 x g for 5 min and 
the supernatant was removed completely. The cell pellet was then resupended in 40 μl 
of buffer per 107 total cells and 10 μl of Biotin-Antibody Cocktail per 107 total cells 
were added. After mixing the suspension was incubated for 10 min at 4-8 ºC. Then the 
suspension was diluted with 30 μl of buffer per 107 total cells and 20 μl of Anti-Biotin 
MicroBeads were added per 107 total cells. The well mixed suspension was incubated 
for 15 min at 4-8 ºC. The cells were washed with buffer by adding 10-20 x labeling 
volume and centrifuged at 400 x g for 5 min. The supernatant was pipetted off 
completely and up to 108 cells were resuspended in 500 μl buffer.  
 
Magnetic separation 
The MACS Separation column LS placed in the magnetic field of the VarioMACSTM 
Separator was rinsed with 3 ml of buffer. The cell suspension was then applied onto 
the column. The cells were allowed to pass through the column and the effluent was 
collected as the fraction of unlabeled cells representing the enriched NK cell fraction. 
Subsequently, the column was washed by adding 3 ml of buffer three times allowing 
the column reservoir to empty before applying the next amount of buffer. The entire 
effluent was collected representing the enriched NK cells. 
For some experiments, the cells retained in the column were eluted and tested as the 
non-NK fraction. The cell fractions suspended in NK cell isolation buffer were 
centrifuged and resuspended in RPMI 1640 containing 2 mM glutamine and 25 mM 
HEPES buffer, supplemented with 10% fetal bovine serum (heat inactivated) and 
gentamycin (50 μg/ml). 
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3.1.3 Culture conditions 
PBMC, purified NK cells and the non-NK fraction were cultured at 0.5 x 106 cells/ml 
in RPMI 1640 containing 2 mM glutamine and 25 mM HEPES buffer, supplemented 
with 10% (v/v) fetal bovine serum (heat inactivated) and gentamycin (50 μg/ml) 
under conditions stated in the figures. Supernatants were frozen for IFN-γ analysis by 
ELISA. 
 
3.1.4 Stimulation with cytokines 
Recombinant TL1A (aa 72-251) was used at 50 ng/ml. Recombinant IL-12 and IL-18 
were used as indicated in the Figure legends. The cytokines tested for the induction of 
DR3 expression on NK cells were used at concentrations as follows: recombinant 
IFN-α, IFN-β, IFN-γ, and IL-2, 200 U/ml; recombinant IL-15, 50 ng/ml and TNF-α, 
10 ng/ml; and Phorbol 12-myristate 13-acetate (PMA) and ionomycin, 10 ng/ml and 
0.2 μg/ml, respectively.  
 
3.2 Culture of tumor cell lines 
 
The cell lines K562, Daudi and SW837 were all grown in RPMI 1640 supplemented 
with 10% (v/v) fetal bovine serum (heat inactivated) and gentamycin (50 μg/ml). 
WiDr cells were cultured in Minimum Essential Medium Eagle with Earle's salts and 
l-glutamine, with 10% (v/v) fetal bovine serum and gentamycin. The cell lines were 
maintained at 37°C in a humidified atmosphere containing 5% CO2. New cultures 
were started at 0.5-1x105 cells/ml. The leukemic suspension cell lines were split to a 
density of 0.2x106 daily or every two days and thus used in the log phase of growth 
for cytotoxicity assays or DR3 induction, respectively.  
The adherent epithelial cell lines were used when reaching approximately 70% 
confluency. They were subcultured 2 times per week at a ratio of 1:3 to 1:5 and 
harvested by using Trypsin EDTA (0.25% Trypsin and 1mM EDTA-4Na) as follows: 
The medium was removed from the plates and the adherent cells were washed with 
PBS w/o Ca2+& Mg2+ in order to completely remove traces of serum which contains 
substrates of trypsin as well as trypsin inhibitor. After adding Trypsin EDTA the 
plates were incubated at 37 ºC and periodically observed under an inverted 
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microscope until the cells had detached from the bottom of the plates. To stop lysis 
new medium was added to the plates. The cells were collected and centrifuged. The 
cell pellet was resuspended in new medium and the cells were dispensed in new 
flasks. 
 
3.3 Flow cytometric analysis 
 
Test principle 
Flow cytometry is a technology that permits the simultaneous analysis of multiple 
physical and biological characteristics of individual cells in a suspension, based on 
light scattering and fluorescent properties (9;51). To this purpose, cells are transported 
to a laser intercept in a fluid stream. When the cells are illuminated by the laser beam, 
they scatter light and cell constituents labeled with fluorescent molecules emit 
flourescence. Scattered and fluorescent light is collected by lenses. Beam splitters and 
filters direct the resulting light signals to detectors which transform the light signals 
into electronic signals. The data on the light scattering and fluorescent properties of 
each particle or event is processed in a computer and can be analysed to provide 
information about subpopulations within a sample. Sorting decisions can further be 
initiated by the electronics system. 
The technique of hydrodynamic focusing is used to ensure optimal illumination of the 
cells by the laser beam. Hereby, the sample is injected into a stream of sheath fluid 
within the flow chamber. The flow of sheath fluid accelerates the cells and precisely 
aligns them in front of the beam of laser light. 
Light scattering depends on a cell’s physical properties, namely its size, membrane 
and internal complexity. Forward-scattered light (FCS), which is proportional to cell-
surface area or size, is diffracted light, detected just off the axis of the incident laser 
beam in the forward direction. Side-scattered light (SSC), which depends on cell 
granularity (or internal complexity), is a measurement of refracted and reflected light, 
collected in approximately 90 degrees to the laser beam. Correlated measurements of 
FSC and SSC permit the differentiation of major leucocyte subpopulations 
(neutrophils, monocytes, lymphocytes). 
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For immunophenotyping, cell constituents, e.g. individual antigenic surface markers 
of a cell, are specifically labeled with monoclonal antibodies conjugated to 
fluorescent dyes (fluorochromes), which are then used to identify cells carrying the 
constituent (positive cells).  
A flourochrome is a compound which absorbs light energy over a characteristic 
spectrum of wavelengths. Due to the absorption of light, an electron in the 
flourochrome is raised to a higher energy level. When the excited electron decays to 
its ground state, it emits the excess energy as a photon of light. This transition of 
energy defines fluorescence.  
As cells pass through the laser beam, each cell carrying a fluorochrome label produces 
a fluorescent signal. The amount of flourescent signal detected is directly proportional 
to the number of flourochrome-conjugated antibodies bound on the cell and 
consequently to the number of copies of the labeled constituent present in the cell. 
Multiple cell constituents or antigens can be detected simultaneously by using 
antibodies conjugated to different fluorochromes. Several flourochromes can be used 
in combination if the wavelength of the laser excites the different fluorochromes and 
if their peak emission wavelengths are far enough apart, so that each fluorescent 
signal can be detected by a separate detector. Modern flow cytometers are equipped 
with multiple lasers with different wavelengths, so that even more fluorochromes can 
be used simultaneously.  
To subtract auto-fluorescence of cells and unspecific binding of the specific antibody 
directed against the cell constituent in question, a sample of cells of each test 
condition is labeled with an isotype control antibody, i.e. an unspecific 
immunoglobulin of the isotype of the specific antibody, and the control is then 
analyzed together with the test samples. A threshold value of fluorescence intensity 
attributed to specifically bound flourochrome-conjugated antibody is defined, which 
is used to demarcate positive from negative cells. 
The following flourochromes were used in this study: 
Flourescein iso-thiocyanate (FITC), peak emission wavelength at 530 nm 
Phycoerythrin (PE), peak emission wavelength at 570 nm 
Tri-Color (TC), peak emission wavelength at 670 nm 
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The staining pattern, combined with FCS and SSC data, allows to identify a particular 
cell type or subpopulation and to count its relative percentage. If the employed 
antibodies are used in excess, it is further possible to compare the mean fluorescence 
intensities of different cell populations and to determine which population expresses a 
greater per cell quantity of the labeled cell constituent. 
 
3.3.1 Evaluation of NK cell purity 
The purity of the NK cell fraction isolated by magnetic-activated cell sorting (cf. 
2.2.1.2) was determined by flow cytometry. To determine the percentage of NK cells, 
T cells, B cells and monocytes in the enriched NK cell fraction, aliquots were directly 
stained for the NK cell marker CD56, the T cell marker CD3 and for the B cell marker 
CD19 or the monocyte marker CD14, respectively. To this end, 1.5x106 cells 
suspended in medium were washed by centrifuging at 400 x g for 5 min, resuspending 
in 1 ml of staining solution (cf. Materials) and subsequent centrifuging. Next, the 
supernatant was removed and the cell pellet was resuspended in 300 μl of staining 
solution (PBS/0.5% (w/v) BSA). The cell suspension was then subdivided in three 
100-μl aliquots of 0.5x106 cells each. Two aliquots were incubated on ice for 30 min 
with 2.5 μl each of anti-CD3 PE-conjugated mAb, of anti-CD56 TC-conjugated mAb 
and of either anti-CD19 FITC-conjugated mAb or anti-CD14 FITC-conjugated mAb, 
respectively. The third aliquot incubated with 5 μl each of mouse IgG1-TC-
conjugated and of mouse IgG2a-PE conjugated served as isotype control. The aliquots 
were washed afterwards with staining solution and the cells were fixed in 300 μl of 
PBS/1% (w/v) Paraformaldehyd by adding 150 μl of staining solution (PBS/0.5% 
(w/v) BSA) to the cell pellets, vortexing and diluting with 150 μl of fixing solution 
(PBS/2% (w/v) Paraformaldehyd). Expression of CD56, CD3 and CD19 or CD14, 
respectively, on the enriched NK cell fraction was analyzed by flow cytometry. Based 
on forward and side scatter the gate was set to include lymphocytes and monocytes 
and to exclude cellular debris and aggregates. 5x104 cells were acquired. FITC was 
acquired on the FL-1 fluorescence detector, PE on FL-2 and TC on FL-3 using log 
amplification. Percentage non-specific staining by isotype control Ab was substracted 
from percentage specific staining of the test condition. 
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The flow cytometric analysis revealed a yield of a population of greater than 95% 
CD56+, CD3- NK cells in all experiments. 
 
3.3.2 Analysis of DR3 surface expression  
Test principle 
To study surface NK cell DR3 expression, NK cells were indirectly labeled with an 
anti-DR3 specific monoclonal antibody or an isotype control antibody, respectively, 
as primary labeling reagent, and an anti-mouse antibody conjugated to phycoerythrin, 
as secondary labeling reagent. After blocking with mouse IgG to prevent unspecific 
binding, the cells were further stained for CD3 and CD 56 to evaluate DR3 surface 
expression of NK cells (CD3-, CD56+), T cells (CD3+, CD56-) and NKT cells 
(CD3+, CD56+) by flow cytometric analysis. 
 
Procedure 
0.5x106 PBMC per staining condition were washed with staining solution (PBS/0.5% 
(w/v) BSA). After centrifuging for 5 min at 400xg the cell pellet was resuspended in 
100 μl of staining solution per 0.5x106 PBMC. Next, the cell suspension was 
subdivided in 100 μl-aliquots of 0.5x106 PBMC per stainining condition. To prevent 
unspecific binding of the subsequently used antibodies the aliquots were blocked with 
1 μl goat IgG each for 20 min on ice (without subsequent washing). Next, the aliquots 
were incubated with 2 mg anti-DR3 specific monoclonal antibody or 10 μl isotype 
control antibody (mouse IgG1) on ice for 30 min. The aliquots were then washed with 
staining solution to remove excess unbound antibodies and incubated with 2.5 μl anti-
mouse IgG1 secondary antibody conjugated to phycoerythrin for 30 min on ice. After 
washing with PBS/0.5% (w/v) BSA and blocking with 1 μl of mouse IgG for 20 min 
on ice, all aliquots were stained with 2.5 μl CD3-FITC and CD56-TC for 20 min on 
ice, fixed in PBS/1% Paraformaldehyd and analyzed by flow cytometry. DR3 
expression was analyzed on NK cells by gating on lymphocytes based on forward and 
side scatter and further gating on CD3-CD56+ cells. FITC was acquired on the FL-1 
fluorescence detector, PE on FL-2 and TC on FL-3 using log amplification. 5x104 
cells were acquired and both the percentage of NK cells expressing DR3 and the mean 
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fluorescence intensity of DR3-positive cells were obtained. Percentage non-specific 
staining by isotype control Ab was subtracted from percentage specific staining of the 
test condition. 
 
3.3.3 Analysis of intracellular IFN-γ production 
Test principle 
For analysis of intracellular IFN-γ production, cytokine-activated PBMC were 
incubated with Brefeldin A for the last 4 hrs of the incubation time. Brefeldin A is a 
lactone antibiotic produced by fungal organisms, which inhibits protein secretion of 
cells by interfering with anterograde protein transport from the endoplasmatic 
reticulum (ER) to the Golgi apparatus (38;57). Proteins thus accumulate inside the ER 
and can be detected intracellularly by fluorochrome-conjugated monoclonal 
antibodies. To this end, PMBC were surface-stained with flourochrome-conjugated 
anti-CD3 and anti-CD56 antibodies for the phenotyping of NK cells, T cells and NKT 
cells first. Fixation of the cell structure and the surface staining with formaldehyde 
followed. The cell membrane was then permeabilized with Permeabilization Medium 
(Reagent B, Caltag (South San Francisco, CA)). After the cells had been blocked with 
mouse IgG to prevent unspecific binding, intracellularly accumulated IFN-γ was 
stained with flourochrome-conjugated anti-IFN-γ antibody, which could enter the 
cells through the created pores in the cell membrane. Subsequently, phenotyping of 
the cells and assessment of intracellular IFN-γ production were performed by flow 
cytometry. 
 
Procedure 
PBMC were cultured with IL-12 and IL-18 with or without TL1A for 24, 48 and 72 
hrs. Brefeldin A (10 μg/ml) was added to the cells for the last 4 hrs of the incubation 
time. Next, 0.5x106 PBMC per staining condition were washed with PBS/0.5% (w/v) 
BSA. The cell pellet was resuspended in 100 μl of PBS/0.5% (w/v) BSA per 0.5x106 
PBMC and the cell suspension was subdivided in 100 μl-aliquots of 0.5x106 PBMC 
per stainining condition. All aliquots were stained with 2.5 μl CD3-FITC and CD56-
TC for 20 min on ice. After washing with PBS/0.5% (w/v) BSA and centrifuging, the 
supernatant was removed and the cell pellets were resuspendend by vortexing 
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carefully. 100 μl of Fixation Medium (Reagent A) were added to each aliquot. Next, 
the aliquots were incubated at room temperature for 10 min and washed with 
PBS/0.5% (w/v) BSA. After centrifuging and removing the supernatant the cell 
pellets were resuspendend by vortexing carefully and 100 μl of Permeabilization 
Medium (Reagent B) and 1 μl of mouse IgG were added to the aliquots. The aliquots 
were blocked on ice for 10 min and either 10 μl of anti-IFN-γ PE or of isotype control 
antibody (mouse IgG1-PE) were added. After incubating for 20 min on ice the 
aliquots were washed with permeabilizing solution. The cells were fixed in 300 μl of 
PBS/1% (w/v) Paraformaldehyd by adding 150 μl of permeabilizing solution to the 
cell pellets, vortexing and diluting with 150 μl of fixing solution. Intracellular IFN-γ 
production was analyzed on NK cells by flow cytometry by gating on lymphocytes 
based on forward and side scatter and further gating on CD3-CD56+ cells. 5x104 cells 
were acquired and both the percentage and the mean fluorescence intensity of IFN-γ-
producing NK cells were obtained. Percentage non-specific staining by isotype 
control Ab was subtracted from percentage specific staining of the test condition. 
 
3.4 Detection of IFN-γ by ELISA 
 
Test principle 
The Enzyme-Linked Immunosorbent Assay (ELISA) is used to detect and quantitate 
antibodies or antigens in unknown samples (16).  
The ELISA can be employed for qualitative or quantitative measurements. The 
qualitative ELISA, which examines the presence of a substance in an unknown 
sample, yields negative or positive results. The quantitative ELISA requires that a 
purified standard of the substance to be measured is available. In the quantitative 
ELISA, the optical density of the unknown sample is interpolated into a standard 
curve, composed of a serial dilution of the target antigen. 
Depending on the measured substance different techniques of ELISA are employed. 
The quantitative sandwich ELISA used in this study is a frequently applied technique 
for antigen measurement. Hereby, capture antibody is bound to a solid phase, usually 
the bottom of a microtiter plate well. The antigen-containing unknown samples and 
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the standards which consist of a serial dilution of the antigen are then applied to the 
plate. The antigen is allowed to complex with the bound capture antibody. Unbound 
antigen is then removed by washing the plate, and a detection antibody is allowed to 
bind to the antigen, thereby completing the sandwich. Next, an enzyme-conjugated 
secondary antibody, which binds the Fc region of the detection antibody, is added. 
The wells are washed again, and a substrate is applied to the wells. The substrate is 
converted by the enzyme which catalyzes the formation of a colored product. Color 
development during an incubation period is directly proportional to the amount of 
enzyme-conjugated secondary antibody, which is in proportion to the amount of target 
substance detected. In the quantitative ELISA, the optical density is monitored 
spectophotometrically and related to the concentration of the antigen by calibration to 
the standard curve, composed of a serial dilution of the target antigen. The sandwich 
ELISA can be used if capture and detection antibody recognize separate epitopes on 
the antigen, so that they do not hinder each other’s binding.  
 
Procedure 
IFN-γ was quantitated in culture supernatants by amplified sandwich ELISA. To this 
end, 96 well microtiter plates were coated overnight in a humidified box at 4ºC with 
50 μl/well of monoclonal mouse anti-IFN-γ Ab at 5.0 μg/ml in 1xBorate Buffered 
Saline (BBS). After washing three times with 200 μl/well 1xPBS/Tween the wells 
were blocked with 150 μl/well PBS/0.5% (w/v) BSA for 30 min at room temperature. 
The use of non-human serum protein (bovine serum albumin) prevents non-specific 
binding of proteins antigens in the culture supernatants by anti-IFN-γ Ab. The 
blocking solution was then removed (no washing). 50 μl/well of standards, consisting 
of a serial dilution of recombinant human IFN-γ at 0.2, 0.4, 0.6, 1.2, 1.6, 2.0 and 2.4 
ng/ml, and 50 μl/well of the samples of unknown IFN-γ concentration, both diluted in 
PBS/0.5% (w/v) BSA, were applied to the wells in duplicate for each condition. The 
plates were incubated for 24-72 hrs in a humidified box at 4ºC. Sample and standard 
IFN-γ was detected by adding (no emptying or washing) 50 μl/well of secondary anti-
IFN-γ biotinylated mAb at 0.5 μg/ml in 0.5% (w/v) BSA/PBS and incubating for 2 hrs 
at room temperature in a humidified box. After washing four times with 200 μl/well 
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1xPBS/Tween, the biotinylated mAb was labeled by 100 μl/well of streptavidin-
alkaline phosphatase, diluted 1 to 1000, for 30 min at room temperature in a 
humidified box. The plates were washed two times with 200 μl/well of 1xPBS/Tween 
followed by four phosphate-free washes with 200 μl/well of 1xTris/NaCl. 50 μl/well 
of substrate (0.2 mM NADPH) were added for 30 min, and the NADH signal was 
amplified using 2-propanol (3%) with iodonitrotetrazoliun violet (1 mM), alcohol 
dehydrogenase (75 μg/ml) and diaphorase (50 μg/ml). Color development occurred 
within 15 min at 20ºC. Plates were read at 490 nm on an Emax plate reader. Sample 
concentration was calculated by interpolating the optical density of the samples into a 
standard curve consisting of a serial dilution of IFN-γ, generated with the software 
Elisa Master®, developed by R. Deem (Inflammatory Bowel Disease Center, Cedars-
Sinai Medical Center, Los Angeles, CA). 
 
3.5 51Cr-release assay 
 
Test Prinicple 
The evaluation of NK cell cytotoxicity is dependent upon the labeling of target cells 
with a substance that is released upon disruption of the target cell plasma membrane 
as a result of lysis mediated by effector cells. Although several non-radioactive, 
mostly flow-cytometric techniques are employed to measure cytotoxicity, the 
51Chromium-release assay is considered the gold standard cytotoxicity measure 
(23;36). The 51Cr-release assay primarily measures perforin-mediated osmotic lysis 
(23). Hereby, target cells are incubated with the radioactive 51Chromium and then 
mixed with effector cells. After an incubation period of effector and target cells the 
amount of 51Chromium released from the target cells into the supernatant is directly 
proportional to the number of target cells killed.  
Peripheral blood mononuclear cells, which can be easily obtained by venipuncture, 
are commonly used as effector cells. The cell line K562 is the standard target for 
measurements of cytotoxicity. The NK-sensitive K562 can be used to assess the 
cytolytic acivity mediated by freshly isolated, unstimulated NK cells, while the Daudi 
cell line, which is resistant to lysis by unstimulated NK cells, is frequently used to 
evaluate cytolytic acivity of activated NK cells. The cell lines are maintained under 
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optimal culture conditions in the log phase of growth to ensure reproducible assay 
results. 
In this study, the standard 4-hr incubation period of effector cells and 51Chromium-
labeled target cells was reduced to 2 hrs to shorten the considerable length of the 
assay procedure. Initial experiments had demonstrated that the maximal level of 
cytotoxicity mediated by NK cells during a 2-hr incubation period was not 
significantly different from the maximal level of NK cell cytotoxicity mediated during 
a 4-hr incubation period (Fig. 4.4). 
51Chromium released into supernatants by lysed target cells is determined in triplicate 
for all experimental conditions in a beta counter, and mean cpm is calculated. 
Cytotoxicity is quantified by the percentage of target cells killed (percent specific 
lysis (PSL)). The following formula is used to calculate percent specific lysis:  
PSL = [(ER - SR)/(MR - SR)] x 100  
ER denotes the experimental release mean cpm, SR is the spontaneous release release 
mean cpm, and MR is the maximal release mean cpm.  
Maximal release of 51Chromium results from lysis of all target cells. Spontaneous 
release of 51Chromium refers to lysis of target cells that is not mediated by effector 
cells. It is an indicator of the well-being of the target cells and should not exceed 20 % 
of maximal lysis. 
The determination of PSL is used to assess the validity of the 51Chromium-release 
assay. A valid cytotoxicity assay is characterized by an increasing dose-response 
relationship between PSL and increasing E:T ratios (Fig. 3.1).  
Lytic unit (LU) is the widely preferred and used standard measure of cytotoxicity, as 
it permits an assessment of cytotoxic activity which is independent of any particular 
E:T ratio. It is defined as the number of effector cells that is required to lyse a 
predetermined percentage, commonly 30%, of a specified standard number of target 
cells (TSTD). TSTD was equal to 104 target cells in this study. LU30 was calculated by 
multiplying the E:T ratio which results in 30% lysis of 104 targets by the number of 
targets in the assay (TSTD=104). Usually, results are presented as the number of LU30 
contained in a predetermined number of effector cells (ESTD), in general 107 effector 
cells (Fig. 3.1). Increasing values of the measure LU30/107 effector cells represent an 
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increase of NK cell cytotoxic activity. The measure LU30/107 effector cells 
summarizes the data and facilitates the comparison of test conditions in the NK assay 
(23).  
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Figure 3.1: Results of a representative 2-hr 51Cr-release assay with PBMC. A, Dose-response relationship 
between Percent Specific Lysis and E:T ratios. PBMC were cultured for 96 hrs with medium (Control) or with IL-
12 (40 pg/ml) and IL-18 (54 ng/ml) without or with TL1A (50 ng/ml), and their cytotoxicity was tested against 
Daudi cells in a 2-hr 51Cr-release assay. B, LU30 of a treatment condition was calculated by multiplying the E:T 
ratio which resulted in 30% lysis of 104 targets by the number of targets in the assay (TSTD=104).. Results are 
presented as the number of LU30 contained in a predetermined number of effector cells (ESTD), in general 107 
effector cells ((LU)30/107 effectors).  
 
In summary, lytic units were calculated as:  
LU30/107 effector cells = ESTD/(E:T30) x (TSTD) 
in which ESTD is 107 effector cells (abbreviated: effectors), E:T30 is the E:T ratio at 
which 30% of the target cells are killed and TSTD is 104 target cells. 
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Procedure 
Cytolytic activity was determined by 2-h 51Cr-release assays. K562, Daudi, SW837 
and WiDr were used as target cells. NK cells, non-NK cells, and PBMC were used as 
effector cells. Target cell pellets (3x 106 cells) were labeled with 150 μCi of 51Cr at 
37°C for 1 h with gentle mixing every 15 min. The target cells were washed twice 
with Hanks' Buffered Salt Solution and adjusted to the concentration of 0.1 x 106 
cells/ml in RPMI 1640 medium (supplemented as described above). 1 x 104 target 
cells/well were incubated in 200 μl RPMI 1640 medium with effector cells at 8 
different effector/target (E:T) ratios, ranging from 100:1 to 0.8:1 for PBMC and the 
non-NK cell fraction and from 10:1 to 0.08:1 for purified NK cells.  
To plate effector and target cells at serial E:T ratios effector cells were added to 
triplicate wells of a 96-well V-bottom plate and diluted to appropriate concentrations 
first. To this end, the effector cell concentration was adjusted to 20 x 106 cells/ml for 
PBL and non-NK cells and to 2.0 x 106 cells/ml for purified NK cells. A 100-μl 
aliquot of RPMI 1640 medium (specified above) was dispensed to each testing well of 
a 96-well V bottom plate. Next, 100-μl aliquots of the effector cell suspension were 
applied to row “A” wells in triplicate for each condition of treatment. Serial twofold 
dilutions were performed by mixing the contents of row “A” wells, removing 100-μl 
aliquots of the cell suspension from these wells and adding them to row “B” wells 
with a multi-channel pipettor. The contents of row “B” wells were mixed with the 
multichannel pipettor and the dilution procedure was continued down the plate to row 
“H”. A 100-μl aliquot of the cell suspension was discarded from the final row “H”. As 
a result of this, each well across the row contained 100-μl aliquots of effector cell 
suspension at concentrations ranging from 10 x 106 cells/ml for PBL and non-NK 
cells or 1.0 x 106 cells/ml for purified NK cells in row “A” to 0.07 x 106 cells/ml for 
PBL and non-NK cells or 0.007 x 106 cells/ml for purified NK cells in row “H”. Next, 
100 μl of the 51Cr-labeled target cell suspension, adjusted to 0.1 x 106 cells/ml, were 
added to each well. E:T ratios ranging from 100:1 to 0.8:1 for PBMC and the non-NK 
cell fraction and from 10:1 to 0.08:1 for purified NK cells resulted. Triplicate wells 
containing target cells alone (1 x 104 target cells/200 μl RPMI 1640 medium/well) 
were set up to determine spontaneous release (SR) by adding 100-μl aliquots of RPMI 
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1640 medium and of the target cell suspension. To measure maximum target 51Cr-
release (MR) 100-μl aliquots of 1% Triton X-100, diluted with medium, and of the 
target cell suspension were added to triplicate wells (Fig. 3.2).  
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Figure 3.2: A plating scheme for the cytotoxicity assay with PBMC. A 100-μl aliquot of medium was 
dispensed to each testing well (wells “1” to “9” in rows “A” to “H”) of a 96-well V bottom plate. Effector cell 
suspension (100 μl/well) was applied to row “A” wells in triplicate for each condition of treatment. Serial twofold 
dilutions were performed by mixing the contents of row “A” wells, removing 100-μl aliquots of the cell 
suspension from these wells and adding them to row “B” wells. This dilution procedure was continued down the 
plate to row “H”. A 100-μl aliquot of the cell suspension was discarded from the final row “H”. 100 μl of the 51Cr-
labeled target cell suspension were added to each well, resulting in a total volume of 200 μl per well. SR, 
Spontaneous release; MR, Maximal release. 
 
Assay plates were centrifuged briefly at 200 x g to and incubated at 37°C in an 
atmosphere of 5% CO2 in air for 2-3 h. Next, the supernatants were harvested by 
transfering 80 μl of supernatant from each well to the counting tray containing 80 μl 
of scintillation fluid/well with a multichannel pipettor. 51Cr released into supernatants 
by lysed target cells was measured in a Wallac 1450 Microbeta Liquid Scintillation 
Counter, and mean cpm calculated. The results are reported as lytic units (LU)30/107 
effectors. Percent specific lysis and lytic units were calculated using a computer 
program developed by R. Deem (Cedars-Sinai Medical Center, Los Angeles, CA).  
 
 
34 
                                                                                                                            Methods 
3.6 H3-Thymidine incorporation assay 
 
Test principle 
The H3-Thymidine Incorporation Assay is used to determine proliferation of 
lymphocytes following activation by cytokines or antigens. Cells undergoing 
proliferation display an increased rate of protein and DNA synthesis. The increase in 
DNA synthesis can be assessed by adding H3-Thymidine, a radioisotope-labeled DNA 
precursor, to the culture medium. The amount of DNA taken up by the dividing cells 
is directly proportional to the level of cellular proliferation. The amount of H3-
Thymidine incorporated into cellular DNA is measured in a beta counter. 
 
Procedure 
Purified NK cells were cultured in a 96-well plate at 0.2 x 106 cells/ml for 72 hrs with 
the cytokines IL-12 and IL-18 combined at 5-fold serial dilutions ranging from 108 
ng/ml to 6 ng/ml for IL-18 and from 2000 pg/ml to 8 pg/ml for IL-12, without and 
with TL1A. Tritiated thymidine was diluted with RPMI 1640, supplemented as 
described above, to a concentration of 40 μCi/ml. After removing 100 μl-aliquots of 
supernatant from each treatment condition for measurement of IFN-γ, 100 μl-aliquots 
of tritiated thymidine were added to the wells resulting in a final concentration of 20 
μCi/ml of tritiated thymidine. The plate was incubated for further 24 hrs and then 
frozen at -20°C. The effect of TL1A on NK cell proliferation at titrated concentration 
ratios of IL-12/IL-18 was subsequently determined with liquid scintillation counting. 
After the plates had been thawed, the cells of each treatment condition were harvested 
on a filter mat according to the instructions of the Harvester 96®. Hereby, excess 
tritiated thymidine that had not been incorporated into cellular DNA is removed. The 
filer mat was then dried in an oven for 10 min and sealed in a plastic bag containing 8 
ml of BetaPlateScint. The filter mat was completely immersed in the BetaPlateScint 
with the help of a rubber roller. H3-Thymidine incorporation into the cells of each 
treatment condition was measured in a Wallac 1450 Microbeta Liquid Scintillation 
Counter. The results were reported in counts per minute (cpm). 
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3.7 Statistical analysis 
 
The paired t-test was performed using JMP IN 5.1 data analysis software to determine 
the significance of the difference in cytotoxicity of IL-12/IL-18 treated PBMC 
without and with TL1A.  
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4 Results 
 
4.1 Regulation of DR3 expression on NK cells by cytokines 
 
DR3 is the receptor for TL1A, the only DR3-ligand of several tested by Migone et al 
(52). DR3 is not expressed on non-activated resting NK cells (64). In a previous 
study, Papadakis et al. showed that DR3 could be induced on up to 70% of NK cells 
by maximally effective concentrations of the combined cytokines IL-12 and IL-18, 
while IL-12 or IL-18 alone upregulated DR3 on approximately 20% of NK cells (64).  
 
63.9IL-18 (54 ng/ml) + IL-12 (1000 pg/ml)
1.1TNF-α
5.6IFN-γ
0IL-2+IL-12
0.1IL-2+IL-15
2.6IL-2
2.4IL-15
0.2PMA+Ionomycin
2.3IFN-α+IFN-β+IL-12
1.0IFN-α+IFN-β
0.2IFN-β
0.6IFN-α
0.7Control
% DR3-positive
NK cells
Culture Condition
 
Table 4.1: Regulation of DR3 expression on NK cells by cytokines. PBMC were incubated with medium 
(Control) or with cytokines alone or in combination as indicated for 48 hrs or with PMA+Ionomycin for 18 hrs, 
stained indirectly for DR3 and analyzed by flow cytometry. Percentage of DR3 specific staining in the NK cell 
population (CD56+CD3-cells) is shown for each culture condition. Percentage specific staining by isotype control 
Ab was subtracted from percentage specific staining of the test condition. 
 
Other cytokines known to activate NK cells (12) might also induce DR3 expression. 
We, therefore, tested several of these stimuli for DR3 up-regulation. To this end, 
freshly isolated PBMC were cultured for 24 and 48 hrs with the cytokines specified in 
Table 4.1 or for 18 hrs with PMA + ionomycin and DR3 expression was analyzed on 
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the NK cell subset, as described in Methods. Only IL-12/IL-18, of a panel of 
cytokines and cytokine combinations tested, was capable of significant induction of 
DR3 (Table 4.1).  
 
4.2 Dose-kinetic analysis of the effect of IL-12/IL-18 on NK cell  
IFN-γ production and proliferation and effect of co-stimulatory  
TL1A 
 
4.2.1 NK cell IFN-γ production at titrated concentrations of IL-12/IL-18  
and effect of co-stimulatory TL1A 
To identify concentrations of the DR3-inductive cytokines IL-12 and IL-18 which 
result in maximal effectiveness of the TL1A-DR3 pathway, NK cell IFN-γ production 
at titrated concentrations of IL-12 and IL-18 was determined and the effect of TL1A 
was studied in each condition. 
To this end, purified NK cells were cultured in a 96-well plate at 0.2 x 106 cells/ml for 
72 hrs with the cytokines IL-12 and IL-18 combined at 5-fold serial dilutions ranging 
from 108 ng/ml to 6 ng/ml for IL-18 and from 2000 pg/ml to 8 pg/ml for IL-12, 
without or with TL1A. Culture supernatants were collected for IFN-γ analysis (Fig. 
4.1A). The fold increase in IFN-γ production induced by TL1A was calculated (Fig. 
4.1B). 
Fig. 4.1A shows that the combined cytokines IL-12/IL-18 dose-dependently augment 
IFN-γ production. A maximum was reached when IL-12 was used at 1000 pg/ml, 
while using IL-18 at 108 ng/ml, without and with TL1A. Remarkably however, the 
TL1A-induced fold increase in IFN-γ production was comparable at the various 
concentration ratios of the two cytokines. The TL1A-induced fold increase ranged 
from 2.0 to 3.1, with an average of 2.6; hereby, very low concentration ranges of IL-
12 and IL-18 (combinations of IL-18 with 8 pg/ml of IL-12; combinations of 40 and 
200 pg/ml of IL-12 with 6 ng/ml of IL-18), which deviated significantly from the 
average, were not taken into account. The synergistic effect of TL1A on IFN-γ 
production at both sub-optimal and optimal concentrations of IL-12 and IL-18 
suggested an efficient upregulation of DR3 on a large proportion of NK cells even at 
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sub-optimal concentrations of IL-12/IL-18, when total IFN-γ production was 
markedly reduced. 
Figure 4.1: NK cell IFN-γ production at titrated concentrations of IL-12/IL-18 and the effect of co-
stimulatory TL1A. A, Purified NK cells were cultured at 0.2 x 106 cells/ml for 72 hrs with the cytokines IL-12 
and IL-18 combined at 5-fold serial dilutions ranging from 108 ng/ml to 6 ng/ml for IL-18 and from 2000 pg/ml to 
8 pg/ml for IL-12, without and with co-stimulatory TL1A. The culture supernatants were collected for IFN-γ 
analysis. The amount of IFN-γ accumulating in the culture supernatant over time, as determined by ELISA, is 
shown. B, The fold increase in IFN-γ production induced by TL1A was calculated.  
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4.2.2 NK cell proliferation at titrated concentrations of IL-12/IL-18 and  
effect of co-stimulatory TL1A 
Papadakis et al. had shown by flow cytometry that while in T cells, TL1A enhanced 
IFN-γ production by increasing both the number of IFN-γ producing cells and the 
amount of IFN-γ produced per cell (increase in mean fluorescence intensity), in NK 
cells, only the number of IFN-γ producing cells was significantly augmented in 
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response to TL1A (64). These findings suggested that the synergistic effect of TL1A 
on IL-12/IL-18-induced-IFN-γ production of NK cells was mainly due to NK cell 
proliferation. A 24-h H3 Thymidine incorporation assay was performed to study if this 
observation corresponded to an induction of DNA replication by TL1A and if the 
extent of proliferation varied at different concentrations of IL-12 and IL-18. 
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Figure 4.2: DNA replication of NK cells at titrated concentrations of IL-12 and IL-18 and effect of co-
stimulatory TL1A. A, Purified NK cells were cultured for 72 hrs with the cytokines IL-12 and IL-18 combined at 
5-fold serial dilutions, ranging from 108 ng/ml to 6 ng/ml for IL-18 and from 2000 pg/ml to 8 pg/ml for IL-12, 
without and with TL1A. After removing the culture supernatant from each treatment condition for measurement of 
IFN-γ (cf. 4.2.1), tritiated thymidine was added to the wells and NK cells were incubated for further 24 hrs. The 
extent of cell proliferation in each test condition was then determined by liquid scintillation counting. The results 
are represented in counts per minute. B, The fold increase in proliferation induced by TL1A was calculated.  
 
To this end, purified NK cells were cultured for 72 hrs with the cytokines IL-12 and 
IL-18 combined at 5-fold serial dilutions without and with TL1A, as described above 
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(cf. 4.2.1). After removing 100 μl-aliquots of culture supernatant from each treatment 
condition for measurement of IFN-γ, tritiated thymidine was added to the wells and 
NK cells were incubated for further 24 hrs. The extent of DNA replication at the 
titrated concentrations of IL-12/IL-18 was then determined by liquid scintillation 
counting.  
The counts revealed induction of NK cell DNA replication by IL-12/IL-18, peaking at 
concentrations of 200 or 1000 pg/ml of IL-12 and 54 or 108 ng/ml of IL-18, 
respectively (Fig. 4.2A). Proliferation was further enhanced by co-stimulatory TL1A, 
with TL1A inducing an average fold increase of 2.2 (Fig. 4.2B). 
 
4.3 Effect of TL1A on IL-12/IL-18-induced NK cell cytotoxicity  
against NK-sensitive K562 target cells 
 
Papadakis et al. demonstrated previously that TL1A augments IL-12/IL-18-induced 
IFN-γ production in NK cells by about two-fold, largely due to NK proliferation (64). 
Given the dramatic induction by IL-12/IL-18 of DR3 on NK cells, this study analyzed 
if TL1A affected another NK effector function, cytotoxicity, as well as IFN-γ 
production. A late time-point (72 hrs) was chosen, since TL1A requires 72 hrs for 
maximal augmentation of IFN-γ production of NK and T cells co-stimulated with IL-
12 and IL-18. The reason for this finding and the prolonged kinetics of other TNF-
family members for IFN-γ augmentation is unknown (64;71).  
PBMC and purified NK cells were cultured for 72 hrs with maximally effective 
concentrations of IL-12 and IL-18 (PBMC: 1 ng/ml and 54 ng/ml, respectively; NK 
cells: 400 pg/ml and 135 ng/ml, respectively) without and with TL1A (50 ng/ml). 
PBMC were also incubated with medium only (Control). Since most purified NK cells 
in culture without stimulation died, a control condition of NK cells cultured with 
medium only was not performed. Their cytolytic activity was then tested against the 
standard NK-sensitive target cell line K562 in a 2-h 51Cr-release assay. An incubation 
time of 72 hrs was chosen as DR3 expression on NK cells reaches its peak at 48 hrs 
after combined stimulation with IL-12/IL-18 (unpublished data) and optimal IFN-γ 
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production in response to IL-12/IL-18 and TL1A occurs at 64-72 hrs (64). The culture 
supernatants were collected to measure the IFN-γ production in each condition. 
While the TL1A/DR3 pathway was functional as evidenced by enhanced IFN-γ 
production in response to TL1A (Fig. 4.3, right panels: 2.1-fold increase in PBMC 
and 2.4-fold increase for NK cells), there was no significant difference in cytolytic 
activity with TL1A (Fig. 4.3, left panels).  
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Figure 4.3: Effect of TL1A on IL-12/IL-18-induced NK cell cytotoxicity against NK-sensitive K562 target 
cells. PBMC and purified NK cells (0.5x106/ml; different donors) were cultured for 72 hrs with maximally 
effective concentrations of IL-12 and IL-18 (PBMC: 1 ng/ml and 54 ng/ml, respectively; NK cells: 400 pg/ml and 
135 ng/ml, respectively) without or with TL1A (50 ng/ml). PBMC were also cultured with medium only (Control). 
Cytotoxicity was tested against the NK-sensitive cell line K562 in 51Cr-release assays and expressed in LU30/107 
(left panels). Culture supernatants were collected at 72 hrs and analyzed for IFN-γ content by ELISA (right 
panels). For NK cells, the results are representative of two similar experiments. LU30, the number of effector cells 
required to lyse 30% of a standard number of target cells, here 104 target cells Bars, SD. ND, not determined, since 
most purified NK cells in culture without stimulation died. 
 
To investigate if a 2-h incubation period of 51Cr-labeled target cells with NK cells 
resulted in the same level of percent specific lysis as a 4-h incubation period, a 4-h 
51Cr-release assay was performed under the same experimental conditions as 
described above. A comparable level of cytotoxicity was reached in 2-h and 4-h 51Cr-
release assays (Fig. 4.4A). While TL1A did not significantly enhance cytotoxicity in 
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either assay, it potentiated IL-12/IL-18 induced IFN-γ production of NK cells, as 
determined by analysis of IFN-γ contents in culture supernatants (Fig. 4.4B).  
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Figure 4.4: Comparison of percent specific lysis in a 2-h and a 4-h 51Cr-release assay. A, Purified NK cells 
(0.5x106/ml; different donors) were cultured for 72 hrs with IL-12 and IL-18 (400 pg/ml and 135 ng/ml, 
respectively) without or with TL1A (50 ng/ml). Cytotoxicity was tested against the NK-sensitive cell line K562. 
Percent Specific Lysis (PSL) is shown for the indicated Effector:Target (E:T) ratios in a 2-h and a 4-h 51Cr-release 
assay. B, Culture supernatants were collected at 72 hrs and analyzed for IFN-γ content by ELISA. PSL, Percent 
Specific Lysis. Bars, SD.  
 
While the spontaneous release was markedly reduced in the 2-h 51Cr-release assay, 
the maximal release of 51Chromium was comparable in the 2-h and the 4-h 51Cr-
release assay (Table 4.2). 
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39113901Maximal release (mean 
cpm)
573246Spontaneous release 
(mean cpm)
4-h 51Cr-release assay2-h 51Cr-release assay
 
Table 4.2: Spontaneous and maximal release of 51Chromium in a 2-h and a 4-h 51Cr-release assay. Purified 
NK cells (0.5x106/ml; different donors) were cultured for 72 hrs with IL-12 and IL-18 (400 pg/ml and 135 ng/ml, 
respectively) without or with TL1A (50 ng/ml). Cytotoxicity was tested against the NK-sensitive cell line K562. 
51Chromium release into supernatants following NK-mediated lysis of targets (cf. Fig.4.4), spontaneous release of 
51Chromium by target cells, and maximal release of 51Chromium following osmotic lysis of targets were 
determined in triplicate for all experimental conditions in a beta counter, and mean counts per minute (cpm) were 
calculated. 
 
4.4 Time-kinetic analysis of the effect of TL1A on IL-12/IL-18- 
induced NK cell cytotoxicity against K562 tumor cells  
 
This study further investigated if TL1A had an effect on IL-12/IL-18 induced 
cytotoxicity of NK cells against K562 at altered time courses. The effect of TL1A on 
NK cell cytotoxicity might set in before or after 72 hrs of co-stimulation with IL-
12/IL-18 and TL1A. Also the efficacy of recombinant TL1A might wane over time. 
To avoid a loss of function of TL1A before DR3 had been induced in NK cells by IL-
12/IL-18, TL1A was added to the test conditions only after a 48-h incubation period 
with IL-12/IL-18, when NK cell expression of DR3 had reached its maximum (64). 
The effect of TL1A on IL-12/IL-18 induced cytotoxicity of NK cells against the 
standard K562 target cell line was studied under the same conditions as previously 
reported (IL-12 at 1000 pg/ml, IL-18 at 54 ng/ml, without and with TL1A). 
The results, summed up in the following table (Table 4.3), reveal that TL1A did not 
enhance IL-12/IL-18 induced cytotoxicity of NK cells and PBL at altered time 
courses. The TL1A/DR3 pathway was functional in all test conditions, as evidenced 
by TL1A enhancement of IL-12/IL-18-induced IFN-γ production or proliferation. The 
potentiating effect of TL1A on IL-12/IL-18-induced NK cell IFN-γ production was 
not evident when culturing NK cells with IL-12/IL-18, without and with TL1A, for 24 
hrs or when co-stimulating with TL1A for the last 3 or 6 hrs of a 51-h or 54-h 
44 
                                                                                                                              Results 
incubation period with IL-12/IL-18. However, TL1A was shown to increase the 
proliferation of NK cells under these conditions. The identical donor was used and a 
simultaneous experimental set-up was performed in the experiments where NK cells 
were co-stimulated with TL1A for the last 3 or 6 hrs of a 51-h or 54-h incubation 
period with IL-12/IL-18. 
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Table 4.3: Time-kinetic analysis of the effect of TL1A on NK cell cytotoxicity against K562 tumor cells at 
maximal concentrations of IL-12/IL-18. PBMC or purified NK cells (0.5x106/ml) were cultured with IL-12 and 
IL-18 (1000 pg/ml and 54 ng/ml, respectively) without or with TL1A (50 ng/ml) for the specified incubation times. 
Cytotoxicity was tested against the NK-sensitive cell line K562 in 2-h 51Cr-release assays. Culture supernatants 
were collected at each time point and analyzed for IFN-γ content by ELISA. A 24-h H3 Thymidine incorporation 
assay was performed at 24 hrs of stimulation with IL-12/IL-18 +/-TL1A and when co-stimulating with TL1A for 
the last 6 hrs of a 54-h incubation period with IL-12/IL-18. ND, not determined. 
 
4.5 Effect of low level stimulation with IL-12/IL-18 on NK cell 
DR3 expression and IFN-γ production 
 
The used maximal concentrations of IL-12 and IL-18, while strongly inducing DR3, 
might maximize NK cell cytotoxicity (Fig. 4.3, left panels), and thus obscure an effect 
of TL1A on NK cell cytotoxicity.  
Therefore, it was determined whether a lower concentration of IL-12, with maintained 
IL-18, would effectively induce DR3 expression on NK cells, and perhaps not 
maximally stimulate IFN-γ production and cytotoxicity.  
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The following two experiments analyzed the effect of a reduced concentration of IL-
12 (40 pg/ml) with maintained IL-18 (54 ng/ml) on DR3 up-regulation and 
intracellular IFN-γ production of NK cells.  
 
4.5.1 NK cell DR3 expression at low level stimulation with IL-12 and IL-18 
First, the effects of maximal and reduced concentrations of IL-12 on DR3 expression 
were compared by flow cytometry. 
PBMC were cultured with medium (Control) or a maximal dose of IL-18 (54 ng/ml), 
while using the co-stimulatory IL-12 at either 40 pg/ml (potentially optimal 
stimulation) or at 1000 pg/ml, as used in the previous cytotoxicity experiment 
(maximal stimulation). At 24 and 48 hrs, PBMC were stained with CD3-FITC, CD-56 
tricolor and DR3-PE, and DR3 expression was analyzed in the NK cell subset by flow 
cytometry, as described in Methods.  
After 48 hrs of incubation, when DR3 expression reached a peak in all test conditions, 
a significant induction of DR3 was maintained at low level stimulation with IL-12/IL-
18 (IL-12 reduced to 40 pg/ml, maintained IL-18). The number of DR3-positive NK 
cells at low level stimulation still mounted to 2/3 of the number at maximal 
stimulation (40% vs. 64% at 48 hrs, Fig. 4.5A). A further analysis of the mean 
fluorescence intensity (MFI) of DR3-positive NK cells showed that the amount of 
DR3 expressed on a per cell basis had decreased only marginally at low level 
stimulation with IL-12/IL-18: At 48 hrs, the MFI of DR3-expressing cells was 30 at 
minimal stimulation, compared to a MFI of 40 at maximal stimulation (Fig. 4.5B).  
The effect of TL1A on IL-12/IL-18-induced NK cell DR3 expression cannot be 
assessed in this experimental set-up. Data (not shown) revealed that DR3 expression 
of IL-12/IL-18-activated NK cells was markedly reduced with TL1A, compared to 
without TL1A. This finding could imply that TL1A and the anti-DR3 mAb compete 
for the same epitope of the DR3 receptor or that bound TL1A masks the epitope 
which binds anti-DR3. 
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Figure 4.5: NK cell DR3 expression at low level stimulation with IL-12/IL-18. PBMC were cultured with 
medium (Control) or a maximal dose of IL-18 (54 ng/ml), while using the co-stimulatory IL-12 at either 40 pg/ml 
or at 1000 pg/ml. At 24 and 48 hrs, PBMC were stained with CD3-FITC, CD-56-TC and DR3-PE, and DR3 
expression was analyzed in the NK cell subset by flow cytometry. A, The percentage of DR3-expressing NK cells 
is shown. B, Mean Fluorescence Intensity of DR3 expressing NK cells. The data is representative of two 
experiments with similar results. Percentage non-specific staining by isotype control Ab was subtracted from 
percentage specific staining of the test condition. 
 
4.5.2 Intracellular IFN-γ production of NK cells at low level stimulation 
with IL-12 and IL-18 and effect of co-stimulatory TL1A 
Next, the effect of a reduced concentration of IL-12 (with maintained IL-18) on 
intracellular IFN-γ production of NK cells was studied by flow cytometry. 
PBMC were cultured with medium (Control) or IL-18 (54 ng/ml) and IL-12 at either 
40 pg/ml or at 1000 pg/ml without and with TL1A (50 ng/ml) for 24 and 48 hrs. 
Brefeldin A was added to each treatment condition for the last 4 hrs of the incubation 
time. Cells were stained with CD3-FITC and CD56-tricolor, fixed and permeabilized 
as described in Methods. Fixed and permeabilized cells were stained with anti-IFN-γ-
PE or an isotype control mAb. Intracellular IFN-γ production was analyzed in the NK 
cell subset by flow cytometry.  
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A marked decrease in the percentage of IFN-γ producing NK cells was observed at a 
reduced dose of IL-12 with maintained IL-18 (Fig. 4.6A). Figure 4.6A further shows 
that TL1A modestly increases the percentage of IFN-γ producing NK cells at maximal 
stimulation with IL-12/IL-18 (at 48 hrs: increase from 56% to 61%). Remarkably 
however, the TL1A-induced increase in IFN-γ producing NK cells is more 
pronounced at reduced level stimulation with IL-12/IL-18 (at 48 hrs: increase from 
7% to 16%).  
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Figure 4.6: Intracellular IFN-γ production of NK cells at low level stimulation with IL-12/IL-18 without and 
with co-stimulatory TL1A. PBMC were cultured with medium (Control) or IL-18 (54 ng/ml) and IL-12 at either 
40 pg/ml or at 1000 pg/ml without and with TL1A (50 ng/ml) for 24 and 48 hrs. Brefeldin A was added to each 
treatment condition for the last 4 hrs of the incubation time. Cells were stained with CD3-FITC and CD56-TC, 
fixed and permeabilized as described in Methods. Fixed and permeabilized cells were stained with anti-IFN-γ-PE 
or an isotype control mAb. Intracellular IFN-γ production was analyzed in the NK cell subset by flow cytometry. 
A, The percentage of IFN-γ producing NK cells is shown. B, Mean Fluorescence Intensity of IFN-γ producing NK 
cells. Percentage non-specific staining by isotype control Ab was subtracted from percentage specific staining of 
the test condition. 
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The mean fluorescence intensity (MFI) of IFN-γ producing NK cells is slightly lower 
at low level stimulation with IL-12/18 (at 48 hrs: 27 (without TL1A) and 35 (with 
TL1A)), compared to the MFI at maximal stimulation (at 48 hrs: 44 (without TL1A) 
and 51 (with TL1A)) (Fig. 4.6B). 
 
4.6 Effect of TL1A on NK cell cytotoxicity against NK-sensitive 
K562 target cells at low level stimulation with IL-12 and IL-18 
 
The preceding experiments identified the combination of 54 ng/ml of IL-18 and 40 
pg/ml of IL-12 as a concentration ratio inducing DR3 effectively, while stimulating 
IFN-γ production only moderately. This concentration might fail to maximize NK 
cytotoxicity, so that a potential synergistic effect of TL1A on NK cytotoxicity might 
be revealed.  
This concentration ratio of IL-12/IL-18 was tested in cytotoxicity experiments (Fig. 
4.7, left panels). PBMC and purified NK cells of the same donor were cultured for 72 
and 96 hrs with IL-12 at 40 pg/ml and IL-18 at 54 ng/ml with and without TL1A (50 
ng/ml), and their cytolytic activity was tested against the K562 cell line in a 2-h 51Cr-
release assay. The culture supernatants were collected to measure the IFN-γ 
production in each condition. 
At the reduced concentration of IL-12, cytotoxicity was not decreased, and TL1A still 
did not significantly enhance IL-12/IL-18-induced cytolytic activity of PBMC and 
NK cells. The effect of TL1A on IFN-γ production was unimpaired: TL1A induced a 
marked increase in IFN-γ production by PBMC and NK cells (PBMC 72 hrs: 3.9 
fold/96 hrs: 4.6 fold; NK cells 72 hrs: 1.5 fold/96 hrs: 1.5 fold), which demonstrates 
the functionality of the TL1A/DR3 pathway (Fig. 4.7, right panels).  
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Figure 4.7: Effect of TL1A on the cytotoxicity of PBMC and NK cells against NK-sensitive K562 target cells 
at low level stimulation with IL-12 and IL-18. PBMC and purified NK cells of the same donor (0.5x106/ml) 
were cultured for 72 and 96 hrs with medium (Control) or a maximal dose of IL-18 (54 ng/ml) and a lower dose of 
IL-12 (40 pg/ml) without or with TL1A (50 ng/ml), and their cytotoxicity was tested against the NK-sensitive cell 
line K562 in a 2-h 51Cr-release assay (upper and lower left panel). Culture supernatants were collected at 72 hrs 
and analyzed for IFN-γ content by ELISA (right panels). For PBMC, the results are representative of 3 
experiments. LU30, the number of effector cells required to lyse 30% of a standard number of target cells, here 104 
target cells. Bars, SD. ND, not determined. 
 
4.7 Time-kinetic analysis of the effect of TL1A on NK cell  
cytotoxicity against K562 tumor cells at low level stimulation  
with IL-12/IL-18 
 
TL1A might enhance NK cell-mediated tumor lysis at low level stimulation with IL-
12/IL-18 over a shorter or a more prolonged time-course.  
Therefore, the effect of TL1A on NK cytotoxicity was examined in the same 
conditions for 120 hrs and 144 hrs. PBMC and purified NK cells of one donor or 
PBMC of another donor were cultured for 120 hrs or for 144 hrs, respectively, with 
medium (Control) or IL-12 at a low concentration (40 pg/ml) and IL-18 at a maximal 
dose (54 ng/ml) with and without TL1A (50 ng/ml). Their cytolytic activity was tested 
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against the K562 cell line in a 2-h 51Cr-release assay. The culture supernatants were 
collected to measure the IFN-γ production in each condition. 
No significant difference in NK cell cytotoxicity against K562 targets was detected 
with and without TL1A at 120 or 144 hrs (Fig. 4.8A), while TL1A had a synergistic 
effect on IL-12/IL-18-induced IFN-γ production (Fig. 4.8B). 
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Figure 4.8: Time-kinetic analysis of the effect of TL1A on NK cell cytotoxicity against K562 tumor cells at 
low level stimulation with IL-12/IL-18. PBMC and purified NK cells of one donor or PBMC of another donor 
were cultured for 120 hrs or for 144 hrs, respectively, with medium (Control) or IL-12 at a low concentration (40 
pg/ml) and IL-18 at a maximal dose (54 ng/ml) with and without TL1A (50 ng/ml). Their cytolytic activity was 
tested against the K562 cell line in 51Cr-release assays and expressed in lytic units. Culture supernatants were 
collected to measure the IFN-γ production in each condition. LU30, the number of effector cells required to lyse 
30% of a standard number of target cells, here 104 target cells. Bars, SD. ND, not determined.  
 
TL1A could not be shown to enhance NK cell cytotoxicity against K562 at a reduced 
concentration of IL-12 (with maintained IL-18) at a shorter time course, at 48 or 72 
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hrs, either (Table 4.4). Replicate experiments further confirmed these findings (Table 
4.4).  
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Table 4.4: Time-kinetic analysis of the effect of TL1A on NK cell cytotoxicity against K562 tumor cells at 
low level stimulation with IL-12/IL-18. PBMC or purified NK cells (0.5x106/ml) were cultured with medium or 
a maximal dose of IL-18 (54 ng/ml) and a lower dose of IL-12 (40 pg/ml) without or with TL1A (50 ng/ml) for the 
indicated incubation periods, and their cytotoxicity was tested against the NK-sensitive cell line K562 in a 2 hour 
51Cr-release assay. Culture supernatants were collected at 72 hrs and analyzed for IFN-γ content by ELISA. ND, 
not determined. 
 
4.8 Effect of TL1A on IL-12/IL-18-induced cytotoxicity of PBMC 
tested against cell lines lysed only by activated NK cells 
 
The NK-sensitive cell line K562 (chronic myelogenous leukemia) is the standard 
target for measurements of cytotoxicity, and it can be used to assess the cytolytic 
acivity mediated by freshly isolated, unstimulated NK cells. The Daudi cell line 
(Ebstein-Barr virus-associated Burkitt’s lymphoma), which is resistant to lysis by 
fresh NK cells, is used for assays of cytotoxicity mediated by activated NK cells (23).  
This study investigated whether TL1A had an effect on NK cell lytic activity against 
the NK-resistant target cell lines Daudi, SW837 (rectal adenocarcinoma) and WiDr 
(colorectal adenocarcinoma) (Fig. 4.9).  
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To this end, PBMC were cultured with IL-12 at a reduced concentration (40 pg/ml) 
and IL-18 (54 ng/ml) with and without TL1A (50 ng/ml) for 72 and 96 hrs, and their 
cytolytic activity was tested against the NK-resistant cell lines in 2-h 51Cr-release 
assays. The culture supernatants were collected to measure the IFN-γ production in 
each condition. The results were compared to the cytotoxicity of PBMC cultured 
under the same experimental conditions against NK-sensitive K562 cells (Fig. 4.9, 
upper right panel).  
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Figure 4.9: Effect of TL1A on IL-12/IL-18 induced cytotoxicity of PBMC tested against cell lines lysed only 
by activated NK cells. PBMC were cultured and tested for their cytotoxicity against the NK-resistant target cells 
Daudi (n=7), WiDr (n=3) and SW837 (n=3) in 51Cr-release assays (left upper panel and lower panels) and 
compared to the cytotoxicity toward K562 cells (right upper panel). The results are shown in LU30/107 effector 
cells. Cytotoxicity of IL-12/IL-18 and TL1A treated NK cells toward Daudi cells was significantly higher than 
cytotoxicity induced by IL-12/IL-18 alone (∗ p < 0.0004 at 72 hrs and ∗∗ p < 0.009 at 96 hrs, paired t-test). 
Cytotoxicity of TL1A stimulated NK cells against WiDr and SW837 cells approached significance (WiDr cells: p 
< 0.39 at 72 hrs, p < 0.18 at 96 hrs; SW837 cells: p < 0.11 at 72 hrs, p < 0.05 at 96 hrs, paired t-test). LU30, the 
number of effector cells required to lyse 30% of a standard number of target cells, here 104 target cells. Bars, SEM.  
 
As represented in Fig. 4.9 (upper left panel) as percent increase in LU30 of seven 
independent experiments, TL1A had the most profound effect on PBMC tested against 
Daudi target cells enhancing cytotoxicity 2-fold at 96 hrs of incubation. The effect of 
TL1A on IL-12/IL-18-induced cytotoxicity of PBMC against the NK-resistant 
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epithelial cell lines WiDr and SW837 showed a similar trend (Fig. 4.9, lower panels). 
However, the enhancement of cytotoxicity by TL1A was less pronounced, compared 
to the Daudi cell line, and the difference in LU30 of PBMC cultured with and without 
TL1A was not statistically significant as determined by paired t-test. 
 
4.9 Effect of TL1A on IL-12/IL-18-induced cytotoxicity of  
purified NK cells and cytotoxic T-cells towards NK-resistant 
cell lines  
 
Because T lymphocytes present in PBMC (a subset of human γδ T lymphocytes) are 
capable of lysing Daudi target cells (15), it was necessary to clarify whether the fore-
mentioned observations with PBMC resulted from NK or non-NK cell cytotoxicity. 
NK cells, purified by magnetic cell separation, were tested on Daudi targets, 
compared to the non-NK cell fraction.  
To this end, NK cells, the non-NK cell fraction and PBMC of the same donor were 
incubated with IL-12 (40 pg/ml) and IL-18 (54 ng/ml) with and without TL1A (50 
ng/ml) for 72 and 96 hrs. The cytolytic activity of PBMC, NK cells and non-NK cells 
was tested in 2-h 51Cr-release assays against Daudi. The culture supernatants were 
collected to measure the IFN-γ production in each condition. 
While the non-NK population, which included CD56+ T cells, displayed some 
IL12/IL18 induced cytotoxicity against Daudi cells, which was enhanced by TL1A 
(Fig. 4.10, lower left panel), TL1A had the most significant effect on the lytic activity 
of purified NK cells (Fig. 4.10, middle left panel). TL1A augmented IL-12/IL-18-
induced cytotoxicity by purified NK cells against Daudi by 7-fold compared to a 2-
fold increase in NK cell IFN-γ production (Fig. 4.10, middle right panel). In non-NK 
cells (Fig. 4.10, bottom panels), consisting mostly of T cells, TL1A increased IFN-γ 
production by 7-fold, but cytotoxicity by only 2-fold. These results imply that the 
enhancing effect of TL1A on the cytotoxicity of PBMC against the Daudi cell line is 
mediated mainly by augmenting the cytotoxicity of IL-12/IL-18 activated NK cells.  
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Figure 4.10: Effect of TL1A on IL-12/IL-18 induced cytotoxicity of purified NK cells and cytotoxic T-cells 
towards Daudi. NK (CD56+, CD3-) cells were purified from PBMC by negative selection on a MACS column. 
The cells retained on the column were eluted and designated as the non-NK fraction. NK cells, the non-NK cell 
fraction and unseparated PBMC from the same donor were incubated with medium (Control) or IL-18 at 54 ng/ml 
and IL-12 at 40 pg/ml without or with TL1A (50 ng/ml) for 72 and 96 hrs, and their cytolytic activity was tested 
against Daudi in a 2-h 51Cr-release assay. The results for 96 hrs are shown in LU30/107 effector cells. LU30, the 
number of effector cells required to lyse 30% of a standard number of target cells, here 104 target cells. Bars, SEM. 
ND, not determined. Since most purified NK cells in culture without stimulation died, no control condition of 
unstimulated NK cells cultured for 3 and 4 days could be done. IFN-γ production was measured in culture 
supernatants by ELISA. Mean values and SEM of two experiments are shown. ND, not determined. 
 
TL1A was shown to enhance IL-12/IL-18-induced cytotoxicity of PMBC towards 
Daudi cells by two-fold, while it potentiated the lytic activity of purified NK cells by 
7-fold. The effect of TL1A on IL-12/IL-18-induced NK cell cytotoxicity towards the 
resistant epithelial cell lines WiDr and SW837 might therefore be more pronounced, 
when purified NK cells are used as effectors of the 51Cr-release assay instead of 
unseparated PBMC.  
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The cytotoxicity of NK cells and non-NK cells, purified by magnetic cell separation, 
was therefore tested on WiDr and SW837. To this end, NK cells and the non-NK cell 
fraction of the same donor were incubated with IL-12 (40 pg/ml) and IL-18 (54 
ng/ml) with and without TL1A (50 ng/ml) for 72 and 96 hrs. The cytolytic activity of 
NK cells and non-NK cells was tested in 2-h 51Cr-release assays against WiDr and 
SW837. The culture supernatants were collected to measure the IFN-γ production in 
each condition. 
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Figure 4.11: Effect of TL1A on IL-12/IL-18 induced cytotoxicity of purified NK cells towards WiDr and 
SW837. NK (CD56+, CD3-) cells were purified from PBMC by negative selection on a MACS column. NK cells 
were incubated with IL-18 at 54 ng/ml and IL-12 at 40 pg/ml without or with TL1A (50 ng/ml) for 72 and 96 hrs, 
and their cytolytic activity was tested against WiDr and SW837 in a 2 hour 51Cr-release assay. The results for 96 
hrs are shown in LU30/107 effector cells. LU30, the number of effector cells required to lyse 30% of a standard 
number of target cells, here 104 target cells. Since most purified NK cells in culture without stimulation died, no 
control condition of unstimulated NK cells cultured for 3 and 4 days could be done. The results are representative 
of two similar experiments. Bars, SD. 
 
As reported in Fig. 4.11, TL1A increased IL-12/IL-18-induced cytotoxicity of 
purified NK cells towards WiDr by 1.4-fold and towards SW837 by 2.2-fold.  
Non-NK cells, consisting mainly of T cells, were incapable of mediating lytic activity 
against WiDr and SW837 after stimulation with IL-12/IL-18 without and with TL1A 
(data not shown). 
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TL1A enhancement of IL-12/IL-18-induced NK cytotoxicity against NK-resistant 
colorectal adenocarcinoma-derived epithelial cells was less powerful, compared to the 
NK-resistant B cell line Daudi. However, the results further confirmed a synergistic 
effect of TL1A on IL-12/IL-18-induced NK cytotoxicity against NK-resistant tumor 
cells. 
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5 Discussion 
 
5.1 Summary of the results  
 
The TNF-like protein TL1A was identified as ligand of DR3 and DcR3 when Migone 
et al. tested a panel of TNF-superfamily receptors for binding affinity to TL1A in 
2002 (52), and it is the only known ligand of DR3 to date (98). This study showed 
that only the combination of IL-12 and IL-18, of a panel of cytokines and cytokine 
combinations tested, is capable of significant induction of DR3 on NK cells (Table 
4.1). Combined stimulation with maximally effective concentrations of IL-12 and IL-
18 powerfully induces DR3 expression on up to 70% of NK cells (64). Papadakis et 
al. further showed that IL-12 or IL-18 alone are also capable of moderate induction of 
DR3 on approximately 20% of NK cells (64). The effects of TL1A on NK cell 
functions are thus dependent on IL-12 and IL-18. TL1A might therefore contribute to 
the regulation of NK cell immune responses by IL-12 and IL-18, for example in 
inflammation (71). This conclusion is supported by recent evidence revealing a role of 
TL1A in the pathogenesis of chronic inflammatory conditions, e.g. inflammatory 
bowel disease, rheumatoid arthritis and atherosclerosis (71;98). Moreover, pro-
inflammatory cytokines, including IL-12 and IL-18, are produced by antigen-
producing cells upon stimulation with antigen in host defense against pathogens 
(12;22;72;88), and a substantial infiltration of tumors by inflammatory cells has also 
been reported (75). TL1A could therefore function in vivo as a co-activator of NK cell 
effector functions in host defense both against pathogens and transformed cells. 
 
This study further demonstrated that TL1A synergizes with both sub-optimal and 
optimal concentrations of IL-12 and IL-18 to augment NK cell IFN-γ production (Fig 
4.1). This finding implies that both sub-optimal and optimal concentrations of IL-12 
and IL-18 induce a functional level of DR3 expression on a large proportion of NK 
cells, which was confirmed in a subsequent experiment analyzing DR 3 expression on 
NK cells at maximal and reduced concentrations of IL-12/IL-18 (Fig. 4.5). These 
results are in line with previous findings of Prehn et al., who examined the effect of 
TL1A on IFN-γ production of peripheral blood lymphocytes (PBL) and lamina 
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propria lymphocytes (LPL), pre-treated with PHA and co-stimulated with high-dose 
IL-12 and IL-18 at low or high concentration. Their results implied that TL1A 
synergizes with IL-12 and both low or high dose IL-18 to augment IFN-γ production 
of PBL and LPL (71).  
This study further confirmed the results of Papadakis et al., who showed by flow 
cytometry that only the number of IFN-γ producing cells was augmented in response 
to TL1A, while the amount of IFN-γ produced per cell was not increased (64). This 
observation implied that the synergistic effect of TL1A on IL-12/IL-18-induced IFN-γ 
production is mainly due to stimulation of NK cell proliferation. This study provided 
further evidence for this conclusion by demonstrating that TL1A induced an average 
2.2-fold increase of IL-12/IL-18-induced NK cell DNA replication (Fig. 4.2), which 
was correlated to an average 2.6-fold increase of IL-12/IL-18-induced NK cell IFN-γ 
production by TL1A (Fig. 4.1). 
 
This study further revealed that TL1A, while not affecting lysis of NK-sensitive 
CML-derived K562 cells, strongly stimulates IL-12/IL-18-induced NK cell 
cytotoxicity against NK-resistant Daudi cells (Burkitt’s lymphoma), lysis that is 
completely dependent on NK activation (Fig. 4.9 and Fig. 4.10). Lysis of the 
colorectal adenocarcinoma-derived epithelial cell lines WiDr and SW837 is similarly, 
but less powerfully, stimulated (Fig. 4.9 and 4.11).  
Although only a few target cell lines (K562, Daudi, WiDr, and SW837) were tested 
for susceptibility to lysis by PBMC or purified NK cells activated by IL-12/IL-18 
without and with TL1A, the results suggested that TL1A preferentially potentiates 
lytic activity of NK cells against NK-resistant targets (Daudi, WiDr and SW837), 
while not increasing the already substantial cytolytic activity against NK-sensitive 
targets (K562). Further studies of the effect of TL1A on NK cytotoxicity against 
additional targets will be needed to determine the generality of this action of TL1A.  
 
Interestingly, TL1A resulted in a 2-fold increase in cytotoxicity of Non-NK cells, 
largely T cells, and thus, the effect of TL1A on cytotoxicity is not limited to NK cells. 
The data presented here indicated that TL1A has a greater impact on NK cell-
mediated cytotoxicity against Daudi cells than on NK cell IFN-γ production, as 
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evidenced by a 7 fold enhancement of cytotoxicity versus a 2 fold increase in IFN-γ 
production. For Non-NK cells, consisting of a large majority of T cells, a 7 fold 
increase in IFN-γ production, but only a 2 fold increase in lysis following stimulation 
by TL1A was demonstrated. These results suggest that TL1A stimulates proliferation 
and effector IFN-γ and lytic function in both NK and T cells, but for NK cells 
potentiating the cytolytic activity of activated NK cells predominates, while for T 
cells, stimulation of IFN-γ production and proliferation of a small subset is the main 
effect (64;65). 
 
5.2 Mechanisms potentially involved in TL1A selective 
enhancement of IL-12/IL-18-induced NK cytotoxicity towards 
NK-resistant target cells 
 
This study did not investigate the mechanisms by which TL1A selectively enhances 
NK cytotoxicity against NK-resistant tumor targets. Since augmentation of 
cytotoxicity against NK-resistant targets by TL1A is dependent on IL-12/IL-18, 
TL1A could contribute to IL-12/IL-18-induced modulations of NK lytic mechanisms 
and/or NK-target cell recognition and NK activation. TL1A might enhance IL-12/IL-
18-induced modulations of NK cell-target interactions which confer NK cell 
susceptibility of previously resistant targets. To date, determinants of target cell 
susceptibility to NK cell-mediated lysis and mechanisms of target resistance, 
respectively, have not been fully elucidated. 
 
5.2.1 General mechanisms of tumor resistance to NK cell-mediated lysis  
General mechanisms of tumor resistance to immune surveillance applicable to NK 
cell-mediated lysis have been formulated (19;32). They either affect NK-target cell 
recognition and NK cell activation or the mechanisms of NK cell killing (necrotic and 
apoptotic pathways).  
One possibility of tumor resistance to NK cytotoxicity might be downregulated 
expression of NK activating receptors (e.g. natural cytotoxicity receptors (NCRs), 
NKG2D, 2B4 (CD24)). Soluble ligands for activating receptors can impair NK-target 
cell recognition. Certain tumors release soluble forms of MHC class I-related ligand 
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A (MICA) or ULBP, ligands of the NK cell activating receptor NKG2D, by 
proteolytic cleaving, which in turn impairs the expression of functional NKG2D 
receptor and enables cancer cells to escape NKG2D-mediated cytolytic activity of NK 
cells (28;74;79). It was also reported that sustained localized expression of MICA on 
tumor cells can elicit NKG2D downregulation and impair NK cell-mediated 
cytotoxicity (60). 
Absence or reduced expression of NK cell activating receptor ligands (e.g. MHC 
class-I related molecules (MIC) A and B, ULBP) and upregulation of MHC class I 
molecules at the target cell surface, which activate MHC-specific inhibitory receptors, 
might also interfere with tumor recognition by NK cells (19;32). Tumor cells can 
display apoptosis resistance involving several distinct molecular mechanisms (31). 
Mechanisms of resistance towards the perforin/granzyme pathway of NK cell-
mediated lysis can involve overexpression of the serine protease inhibitor PI-9/SPI-6 
which inhibits granzyme B and is expressed in a variety of human tumors (11;50), or 
impaired binding of perforin to the target cell membrane (42)  
 
5.2.2 Surface phenotype of the NK-sensitive tumor target K562 and the 
NK-resistant tumor cell lines Daudi, SW837 and WiDr 
Phenotypic differences of Daudi and K562 target cells might explain their distinct 
levels of susceptibility to lysis by nonactivated NK cells. However, both Daudi and 
K562 are MHC class I-deficient (10). K562 cells express the MHC class I-related 
molecules ULBP1 and ULBP2 (18), which are ligands to the NK cell activating 
receptor NKG2D, while Daudi cells only express ULBP1 (67). WiDr cells express the 
MHC class I-related chain A and ULBP 2 and 3 (67); it is not known to date if 
SW837 cells also express MHC class I-related molecules. Both Daudi and K562 are 
Fas receptor-negative, which is reflected by the fact that both are resistant to Fas-
mediated apoptotic killing by freshly isolated NK cells (94). NK cell cytotoxicity 
against a large variety of solid tumor lines including colon carcinoma is, however, 
mediated by apoptotic killing only or by both pathways (93). A susceptibility to 
apoptotic killing might therefore complement the low susceptibility of WiDr and 
SW837 to perforin-dependent cytotoxicity of activated NK cells (cf. Fig. 4.9 and 
4.11). 
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It was recently reported that the secreted member of the TNF receptor superfamily 
Decoy receptor 3 (DcR3)/TR6/M68 is overexpressed in many human primary tumors, 
including Epstein-Barr-Virus-associated lyphomas (58) and adenocarcinoma of the 
colon and rectum, as well as the colon adenocarcinoma cell lines SW480 and SW1116 
(7). Know ligands of DcR3 are Fas ligand, LIGHT and TL1A. Binding to DcR3 
blocks the effector functions of these three ligands. Tumor cell release of DcR3, 
which neutralizes the cytotoxic and immunoregulatory effects of Fas ligand, LIGHT 
and TL1A, is therefore regarded as a mechanism of tumor escape to host immune 
response. Recent studies analyzed the multiple effects of DcR3 on many cells (97), 
and surprisingly, Wu et al. demonstrated that DcR3 sensitizes cells to TRAIL-induced 
apoptosis (97). Since TL1A was further able to induce apoptosis in transient systems 
where DR3 and/or the signaling molecules were overexpressed (52;96), the 
TL1A/DcR3 pathway might contribute to NK cell-mediated lysis of DcR3 
overexpressing tumor cells. It has not been analyzed to date if K562, Daudi, WiDr, 
and SW837 express DcR3. If the NK-resistant targets Daudi (Ebstein-Barr virus-
associated Burkitt’s lymphoma), WiDr (colorectal adenocarcinoma) and SW837 
(rectal adenocarcinoma) overexpress DcR3, while K562 (chronic myelogenous 
leukemia) does not express DcR3, a selective effect of membrane-bound TL1A on 
NK cytotoxicity against on Daudi, WiDr and SW837 would be conceivable. 
 
5.2.3 Tumor resistance towards the perforin/granzyme pathway  
The following findings suggest that mechanisms involved in the perforin/granzyme 
pathway might determine target cell susceptibility to lysis by NK cells. 
Lehmann et al. showed that the lack of NK-susceptibility of the tumor target ML-2 is 
caused by a resistance of these cells to cytotoxic effector molecules of nonactivated 
NK cells (42). Perforin from nonactivated NK cells was shown to bind to the cell 
membrane of the NK-sensitive tumor K562, but it did not bind to the surface of the 
NK-resistant target ML-2, derived from a patient with AML. In this context, it was 
demonstrated that activation of NK cells with IL-12 and IL-2 confers NK-
susceptibility of previously resistant targets by enhancing perforin binding to the 
target cell membrane (43). 
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It was furthermore reported that failure of IFN-γ to induce membrane expression of 
platelet-activating factor (PAF) is a mechanism of resistance of Daudi cells and other 
NK-resistant targets to perforin-mediated lysis by NK cells (18). Activation by 
interaction with the tumor targets K562 and Daudi leads to naive NK cell release of 
choline phosphate-containing lysolipids including platelet-activating factor (PAF) in 
addition to perforin. PAF can simultaneously bind to its specific membrane receptor 
and to perforin and contributes to perforin-induced membrane damage in the NK-
sensitive target K562, but does not have an agonistic effect on the lysis of Daudi cells. 
It was shown that IFN-γ secreted from NK cells activated by target cell contact 
induces PAF-receptor expression on perforin-sensitive K562 cells, but not on 
perforin-resistant Daudi cells. Transfection of the PAF-receptor cDNA into MHC 
class I and Fas-receptor negative Daudi cells restored susceptibility to perforin-
induced lysis by naive NK cells.  
Moreover, it was possible to demonstrate that the immunological synapse formed 
between effector and target cell, which provides a microenvironment for the release of 
cytotoxic granules (6;27), displays distinct organization modes during NK cell 
interaction with resistant and susceptible targets (80;95). 
In conclusion, it is conceivable that stimulation of NK cells by cytokines such as IL-
12 and IL-2 or IL-18 preceding target cell contact might elaborate the perforin-
mediated granule exocytosis pathway, for example by inducing the release by NK 
cells of additional cytokines and molecules like platelet-activating factor (PAF) that 
enhance binding of perforin and subsequent target lysis.  
 
5.2.4 Effects of cytokines on NK cell recognition of tumor targets and 
triggering of NK cells 
In order to explain the susceptibility of NK-resistant cells to lysis by activated NK 
cells Moretta et al. postulated that culture of NK cells with cytokines might induce the 
de novo expression of activating receptors that enable NK cells to recognize 
additional ligands on the surface of tumor targets (54). Previously NK-resistant target 
cells could subsequently provide an activating signal to NK cells which is capable of 
overriding the previously dominant inhibition signal. The expression of the natural 
cytotoxicity receptor NKp44, for example, is induced on NK cells upon activation 
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with IL-2 (54). However, the results of Pende et al. suggest that this activating 
receptor is not predominantly involved in NK-cell mediated killing of Daudi cells. 
Pende et al. demonstrated that mAB-mediated masking of NKG2D abrogated the 
cytotoxicity of IL-2-activated NK cells against Daudi cells. This finding suggests that 
NK cell killing of Daudi cells is dependent on signals generated by the NKG2D 
receptor on NK cells, which interacts with ULBP1, a MHC class I-related molecule, 
expressed on Daudi cells (66;67). To date, it has not been shown whether NK 
cytotoxocity against K562, which express NKG2D receptor ligands ULBP 1 and 2 
(18), is NCR and NKG2D-dependent or only NKG2D-dependent. More recently, 
however, there has been evidence that NKG2D might function as a coreceptor rather 
than a primary receptor during NK cell activation (4).  
NKG2D expression and ULBP binding to NK cells were further shown to be 
upregulated in response to IL-12 stimulation of NK cells (82). Contact of unactivated 
NK cells, and potentially γδ T cells, with MHC class I-negative Daudi cells might be 
insufficient to induce an activating signal for NK cell- and/or γδ T cell-mediated lysis 
of Daudi cells. As a consequence of upregulated NKG2D expression and ULPB 
binding, cytokine-activated NK cells and γδ T cells might then respond to such 
signals and lysis of Daudi cells could be triggered.  
Ortaldo et al. furthermore demonstrated that costimulation of the murine activating 
NK cell receptor Ly49D with IL-12 and IL-18 is capable of over-riding signals from 
the inhibitory Ly49G2 receptor for IFN-γ production in vivo and in vitro (63). Like 
the human killer-cell immunoglobulin-like receptors (KIR), murine Ly49 receptors 
have binding specificity for MHC class I alleles and in general display a great 
functional homology to the human KIR (41). Ortaldo et al. showed that IL-12 and 
Ly49D crosslinking resulted in elevated sustained biochemical activation of STAT4 
and IFN-γ mRNA (63). Since IL-12 and IL-18 synergistic induction of IFN-γ mRNA 
is the result of a STAT4-dependent increase in AP-1 binding to the IFN-γ promoter 
(55), Ortaldo et al. proposed that this signaling pathway could also be involved in 
their finding (63). Moreover, Ortaldo et al. were recently able to extend their evidence 
for synergistic action of NK cell receptors and cytokines to additional NK cell 
activating receptors which use distinct signal transduction pathways (62). In murine 
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NK cells, the DAP12-associated receptor Ly49H, the TCRζ-associated receptor 
NKRp1, and the DAP10- and DAP12-associated receptor NKG2D were shown to 
synergize with IL-12 or IL-18 in the induction of IFN-γ, both in the absence and 
presence of signals from the inhibitory Ly49G2 receptor. Interestingly, co-regulation 
of inhibiting and activating receptors by cytokines was also found in T cells and NKT 
cells (62). Ortaldi et al. showed that the synergistic response of IL-12 and the NK 
activating receptors Ly49D and NKG2D required both the p38 MAP kinase and the 
ERK-dependent signal transduction pathways, which converge to enhance expression 
of the Ifng gene (62). 
These results show that NK receptors cooperate with cytokines mediating NK cell 
effector functions and that co-stimulation of NK receptors with cytokines can reverse 
otherwise dominant inhibitory signals. A similar mechanism might also explain IL-
12/IL-18-induced NK cell lysis of NK-resistant tumor cells. 
 
5.2.5 Signal transduction pathways regulated by IL-12, IL-18 and TL1A 
Even with all of these findings it is not clear which mechanisms may account for the 
enhancing effect of TL1A on IL-12/IL-18-induced NK cell cytotoxicity against NK-
resistant targets.  
TL1A has been shown to activate NF-κB and MAPK (JNK, p38 and ERK1) in the 
human erythroleukemic cell line TF-1 (96). Moreover, interaction of TL1A with its 
receptor DR3 was recently reported to induce IL-8 gene expression by activating 
TRAF2 and NF-κB via the TAK1/ASK1-MKK4/MKK7-JNK2 kinase cascade (98). 
Binding of IL-18 to its receptor (IL-1 receptor-related protein (IL-1Rrp)) induces 
activation of IL-1-receptor-associated kinase (IRAK-1 and IRAK-4), TNFR-
associated factor-6 (TRAF6), NF-κB and JNK (which in turn activates AP-1) in NK 
and Th1 cells (3;83). Experiments analyzing the signal transduction of IL-18 in the 
NK cell line 92 suggest that mitogen-activated protein kinases (MAPKs) p42erk-2, 
p44erk-1, p38 and STAT3 might also play a role in IL-18 responses (35).  
Binding of IL-12 to its specific receptor complex leads to activation of the Janus 
kinases TYK2 and JAK2, resulting in phosphorylation and activation of signal 
transducer and activator of transcription (STAT) 4 and other STATs (12;99). STAT4 
plays a pivotal role in all biological responses induced by IL-12, including IFN-γ 
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production (12). IL-12 also activates p38 mitogen-activated protein kinase (MAPK) in 
NK cells and T cells (99;100). 
The synergistic effects of IL-12 and IL-18 could be the consequence of reciprocal 
upregulation of receptors and of cooperative action at the transcriptional level 
resulting in optimal activation of IFN-γ transcription and other effector functions of T 
and NK cells (3;55).  
By cooperating with IL-12 and IL-18 in the activation of these signaling pathways 
TL1A could contribute to tumor recognition and activation of NK cells and/or NK 
cell lytic mechanisms and thereby maximize NK cytotoxicity against NK-resistant 
target cells. 
 
5.2.6 Potential role of TL1A in activation-induced cell death of NK cells 
Alternatively, TL1A might enhance IL-12/IL-18-induced NK cytotoxicity by 
promoting NK cell survival and recycling for continous killing of target cells. After 
lysing a susceptible target a NK cell can prepare to kill again, become inactivated or 
undergo activation-induced cell death (45). Contact with susceptible targets usually 
induces sustained inactivaton of NK cells and reduces the ability to mediate lysis of 
additional target cells (2;69), due to depletion of effector molecules and/or 
postreceptor desensitization (8;26). Although cytokines can enhance NK cell 
responsiveness and recovery of lytic activity, IL-2 and IL-12-activated NK cells are 
particularly susceptible to activation-induced cell death upon contact with susceptible 
targets and FcR-specific ligands (5;21;33;61). TL1A could inhibit activation-induced 
cell death of NK cells, as DR3-induced NF-κB activation was shown to be 
responsible for resistance to apoptosis in TF-1 cells (96). It remains unclear why this 
would selectively affect NK cell-mediated lysis of NK-resistant targets. 
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5.3 Conclusion 
 
This study demonstrated that TL1A selectively enhances IL-12/IL-18-induced NK 
cell cytotoxicity against Daudi cells and other NK-resistant tumor targets, susceptible 
to lysis only by activated NK cells. TL1A thereby markedly potentiates the lytic 
activity of activated NK cells. The striking induction of DR3 on NK cells by the 
activating cytokines IL-12 and IL-18 would make possible a powerful enhancement 
of NK cytotoxicity in inflammatory sites where TL1A is expressed.  
The signaling pathways involved in TL1A enhancement of IL-12/IL-18-induced 
cytotoxicity and the mechanisms underlying its preferential effect on NK cell-
mediated lysis of resistant targets deserve further attention, and may elucidate a 
possible role for TL1A in tumor surveillance and therapy. 
Specifically, the following points should be addressed. The panel of target cells 
should be extended to determine the generality of the demonstrated effect of TL1A on 
NK cytotoxicity. Hereby, it would be interesting to assess if TL1A-activated NK cells 
acquire the ability to kill selectively certain types of targets (e.g. B cell lines). Tumor 
targets could also be evaluated for DcR3 expression. 
The surface phenotype of NK cells co-stimulated by IL-12/IL-18 and TL1A could be 
analyzed, since TL1A might affect surface expression and function of NK cell 
triggering receptors (CD16, NCR, NKG2D, CD244) as well as receptors induced 
upon NK cell activation (CD69, CD70, Nkp44). 
It would further be warranted to analyze the effect of TL1A stimulation on the 
perforin/granzyme pathway, in particular the perforin granule content, as well as the 
other NK cell lytic mechanisms, i.e. the Fas ligand- and TRAIL-dependent pathways. 
Finally, the hypothesis that TL1A may protect NK cells from activation-induced cell 
death could be assessed. 
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6 Abstract 
 
TL1A (TNFSF15) is a recently identified cytokine belonging to the TNF super-
family, a ligand for death domain receptor 3 (TNFRSF25 or DR3), which is induced 
by activation on T cells and natural killer (NK) cells. TL1A augments IFN-γ 
production by IL-12/IL-18 responsive human T cells by 10-fold or more. Although 
IL-12/IL-18 induces DR3 expression on most NK cells, addition of TL1A increases 
IFN-γ production by only 2-fold. This study, therefore, investigated whether the 
TL1A-DR3 pathway is also implicated in another IL-12/IL-18-regulated NK cell 
function: lysis of tumor cells. The effect of TL1A on IL-12/IL-18-induced NK cell 
cytotoxicity was tested in 51Cr-release assays. 
While TL1A had no additional effect on IL-12/IL-18 induced cytotoxicity against an 
NK-susceptible tumor (K562), TL1A promoted cytotoxicity against NK-resistant 
targets (Daudi), susceptible to lysis only by activated NK cells. Thus, with IL-12/IL-
18 activation, TL1A enhanced lysis of Daudi by both PBMC (2-fold) and purified NK 
cells (7-fold). TL1A also increased lysis of the colorectal adenocarcinoma epithelial 
derived lines (WiDr and SW837) by IL-12/IL-18 activated cells, but to a lesser 
degree. TL1A markedly increased cytotoxicity of IL-12/IL-18 activated NK cells 
against targets cells dependent on NK activation for lysis, and could function in vivo 
as a key co-activator of NK cytotoxicity.  
This study further established by flow cytometry, ELISA or H3-Thymidine 
incorporation assay, respectively, that only combined IL-12/IL-18, of a panel of 
cytokines and cytokine combinations tested, was capable of significant induction of 
DR3 on NK cells, that TL1A synergized with both optimal and sub-optimal 
concentrations of IL-12 and IL-18 to enhance NK cell IFN γ production, and that this 
effect was mainly due to NK cell proliferation. 
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